{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:55:23Z","timestamp":1786704923842,"version":"build-2736575974"},"reference-count":311,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10557-025-07673-6","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T01:09:33Z","timestamp":1740532173000},"page":"317-345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Doxorubicin-Induced Cardiac Remodeling: Mechanisms and Mitigation Strategies"],"prefix":"10.1007","volume":"40","author":[{"given":"Yanna","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9716-733X","authenticated-orcid":false,"given":"Xiaofang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"7673_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10517-005-0138-0","volume":"138","author":"E Lushnikova","year":"2004","unstructured":"Lushnikova E, Klinnikova M, Molodykh O, Nepomnyashchikh L. Morphological manifestations of heart remodeling in anthracycline-induced dilated cardiomyopathy. Bull Exp Biol Med. 2004;138:607\u201312. https:\/\/doi.org\/10.1007\/s10517-005-0138-0","journal-title":"Bull Exp Biol Med"},{"issue":"6","key":"7673_CR2","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","volume":"52","author":"Y Octavia","year":"2012","unstructured":"Octavia Y, Tocchetti CG, Gabrielson KL, et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213\u201325. https:\/\/doi.org\/10.1016\/j.yjmcc.2012.03.006","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"7673_CR3","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00210-023-02382-z","volume":"396","author":"PL Dulf","year":"2023","unstructured":"Dulf PL, Mocan M, Coad\u0103 CA, et al. Doxorubicin-induced acute cardiotoxicity is associated with increased oxidative stress, autophagy, and inflammation in a murine model. Naunyn Schmiedebergs Arch Pharmacol. 2023;396(6):1105\u201315. https:\/\/doi.org\/10.1007\/s00210-023-02382-z","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"7673_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijcha.2015.11.004","volume":"10","author":"MA Mitry","year":"2016","unstructured":"Mitry MA, Edwards JG. Doxorubicin induced heart failure: Phenotype and molecular mechanisms. Int J Cardiol Heart Vasc. 2016;10:17\u201324. https:\/\/doi.org\/10.1016\/j.ijcha.2015.11.004","journal-title":"Int J Cardiol Heart Vasc"},{"key":"7673_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11936-020-00842-w","volume":"22","author":"CW Hoeger","year":"2020","unstructured":"Hoeger CW, Turissini C, Asnani A. Doxorubicin cardiotoxicity: pathophysiology updates. Curr Treat Options Cardio Med. 2020;22:1\u201317. https:\/\/doi.org\/10.1007\/s11936-020-00842-w","journal-title":"Curr Treat Options Cardio Med"},{"issue":"3","key":"7673_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/s0378-4274(01)00329-0","volume":"121","author":"S Zhou","year":"2001","unstructured":"Zhou S, Palmeira CM, Wallace KB. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett. 2001;121(3):151\u20137. https:\/\/doi.org\/10.1016\/s0378-4274(01)00329-0","journal-title":"Toxicol Lett"},{"key":"7673_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cbi.2015.12.010","volume":"244","author":"R Wu","year":"2016","unstructured":"Wu R, Wang H-L, Yu H-L, et al. Doxorubicin toxicity changes myocardial energy metabolism in rats. Chem Biol Interact. 2016;244:149\u201358. https:\/\/doi.org\/10.1016\/j.cbi.2015.12.010","journal-title":"Chem Biol Interact"},{"issue":"2\u20133","key":"7673_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.tox.2010.01.019","volume":"270","author":"RA Carvalho","year":"2010","unstructured":"Carvalho RA, Sousa RP, Cadete VJ, et al. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology. 2010;270(2\u20133):92\u20138. https:\/\/doi.org\/10.1016\/j.tox.2010.01.019","journal-title":"Toxicology"},{"issue":"8","key":"7673_CR9","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3390\/life12081275","volume":"12","author":"D Zahler","year":"2022","unstructured":"Zahler D, Arnold JH, Bar-On T, et al. Valvular heart disease following anthracycline therapy\u2014is it time to look beyond ejection fraction? Life. 2022;12(8):1275. https:\/\/doi.org\/10.3390\/life12081275","journal-title":"Life"},{"issue":"4","key":"7673_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jjcc.2020.10.007","volume":"77","author":"T Kinoshita","year":"2021","unstructured":"Kinoshita T, Yuzawa H, Natori K, et al. Early electrocardiographic indices for predicting chronic doxorubicin-induced cardiotoxicity. J Cardiol. 2021;77(4):388\u201394. https:\/\/doi.org\/10.1016\/j.jjcc.2020.10.007","journal-title":"J Cardiol"},{"key":"7673_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4172\/pharmaceutical-sciences.1000235","volume":"79","author":"M Mobaraki","year":"2017","unstructured":"Mobaraki M, Faraji A, Zare M, et al. Molecular mechanisms of cardiotoxicity: a review on major side-effect of doxorubicin. Indian J Pharm Sci. 2017;79:335\u201344. https:\/\/doi.org\/10.4172\/pharmaceutical-sciences.1000235","journal-title":"Indian J Pharm Sci"},{"issue":"2","key":"7673_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1177\/1078155220965674","volume":"27","author":"K Ghasemi","year":"2021","unstructured":"Ghasemi K, Vaseghi G, Mansourian M. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: a network meta-analysis of metastatic breast cancer. J Oncol Pharm Pract. 2021;27(2):414\u201327. https:\/\/doi.org\/10.1177\/1078155220965674","journal-title":"J Oncol Pharm Pract"},{"issue":"Pt 2","key":"7673_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.116896","volume":"238","author":"Y Liao","year":"2023","unstructured":"Liao Y, Meng Q. Protection against cancer therapy-induced cardiovascular injury by planed-derived polyphenols and nanomaterials. Environ Res. 2023;238(Pt 2): 116896. https:\/\/doi.org\/10.1016\/j.envres.2023.116896","journal-title":"Environ Res"},{"key":"7673_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.117264","volume":"244","author":"K Li","year":"2024","unstructured":"Li K, Chen W, Ma L, Yan L, Wang B. Approaches for reducing chemo\/radiation-induced cardiotoxicity by nanoparticles. Environ Res. 2024;244:117264. https:\/\/doi.org\/10.1016\/j.envres.2023.117264","journal-title":"Environ Res"},{"issue":"1","key":"7673_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5935\/abc.20160005","volume":"106","author":"PS Azevedo","year":"2016","unstructured":"Azevedo PS, Polegato BF, Minicucci MF, Paiva SA, Zornoff LA. Cardiac remodeling: concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment. Arq Bras Cardiol. 2016;106(1):62\u20139. https:\/\/doi.org\/10.5935\/abc.20160005","journal-title":"Arq Bras Cardiol"},{"issue":"3","key":"7673_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1253\/circj.CJ-18-0063","volume":"82","author":"T Anzai","year":"2018","unstructured":"Anzai T. Inflammatory mechanisms of cardiovascular remodeling. Circ J. 2018;82(3):629\u201335. https:\/\/doi.org\/10.1253\/circj.CJ-18-0063","journal-title":"Circ J"},{"issue":"25","key":"7673_CR17","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1161\/circulationaha.110.942268","volume":"122","author":"I Kehat","year":"2010","unstructured":"Kehat I, Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation. 2010;122(25):2727\u201335. https:\/\/doi.org\/10.1161\/circulationaha.110.942268","journal-title":"Circulation"},{"issue":"4","key":"7673_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/jb\/mvae031","volume":"176","author":"M Nishida","year":"2024","unstructured":"Nishida M, Mi X, Ishii Y, Kato Y, Nishimura A. Cardiac remodeling: novel pathophysiological mechanisms and therapeutic strategies. J Biochem. 2024;176(4):255\u201362. https:\/\/doi.org\/10.1093\/jb\/mvae031","journal-title":"J Biochem"},{"issue":"15","key":"7673_CR19","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.jacc.2018.02.021","volume":"71","author":"A Gonz\u00e1lez","year":"2018","unstructured":"Gonz\u00e1lez A, Schelbert EB, D\u00edez J, Butler J. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol. 2018;71(15):1696\u2013706. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.021","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"7673_CR20","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.jacc.2020.03.019","volume":"75","author":"J D\u00edez","year":"2020","unstructured":"D\u00edez J, Gonz\u00e1lez A, Kovacic JC. Myocardial interstitial fibrosis in nonischemic heart disease, part 3\/4: JACC focus seminar. J Am Coll Cardiol. 2020;75(17):2204\u201318. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.019","journal-title":"J Am Coll Cardiol"},{"key":"7673_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.phrs.2016.10.015","volume":"114","author":"AB Garc\u00eda-Redondo","year":"2016","unstructured":"Garc\u00eda-Redondo AB, Aguado A, Briones AM, Salaices M. NADPH oxidases and vascular remodeling in cardiovascular diseases. Pharmacol Res. 2016;114:110\u201320. https:\/\/doi.org\/10.1016\/j.phrs.2016.10.015","journal-title":"Pharmacol Res"},{"issue":"9","key":"7673_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11936-017-0573-z","volume":"19","author":"J Chandrasekhar","year":"2017","unstructured":"Chandrasekhar J, Dangas G, Mehran R. Valvular heart disease in women, differential remodeling, and response to new therapies. Curr Treat Options Cardiovasc Med. 2017;19(9):74. https:\/\/doi.org\/10.1007\/s11936-017-0573-z","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"4","key":"7673_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11897-017-0343-y","volume":"14","author":"N Suthahar","year":"2017","unstructured":"Suthahar N, Meijers WC, Sillj\u00e9 HH, de Boer RA. From inflammation to fibrosis\u2014molecular and cellular mechanisms of myocardial tissue remodelling and perspectives on differential treatment opportunities. Curr Heart Fail Rep. 2017;14(4):235\u201350. https:\/\/doi.org\/10.1007\/s11897-017-0343-y","journal-title":"Curr Heart Fail Rep"},{"key":"7673_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2021.108952","volume":"708","author":"X Fu","year":"2021","unstructured":"Fu X, Tang J, Wen P, Huang Z, Najafi M. Redox interactions-induced cardiac toxicity in cancer therapy. Arch Biochem Biophys. 2021;708:108952. https:\/\/doi.org\/10.1016\/j.abb.2021.108952","journal-title":"Arch Biochem Biophys"},{"issue":"12","key":"7673_CR25","doi-asserted-by":"publisher","first-page":"6534","DOI":"10.1111\/jcmm.15305","volume":"24","author":"N Osataphan","year":"2020","unstructured":"Osataphan N, Phrommintikul A, Chattipakorn SC, Chattipakorn N. Effects of doxorubicin-induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: Insights for future interventions. J Cell Mol Med. 2020;24(12):6534\u201357. https:\/\/doi.org\/10.1111\/jcmm.15305","journal-title":"J Cell Mol Med"},{"key":"7673_CR26","doi-asserted-by":"publisher","unstructured":"Kitakata H, Endo J, Ikura H, et al. Therapeutic targets for DOX-induced cardiomyopathy: role of apoptosis vs. ferroptosis. Int J Mol Sci. 2022;23(3):1414. https:\/\/doi.org\/10.3390\/ijms23031414","DOI":"10.3390\/ijms23031414"},{"issue":"4","key":"7673_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","volume":"12","author":"E Christidi","year":"2021","unstructured":"Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021;12(4):339. https:\/\/doi.org\/10.1038\/s41419-021-03614-x","journal-title":"Cell Death Dis"},{"key":"7673_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.taap.2016.01.006","volume":"293","author":"M Pecoraro","year":"2016","unstructured":"Pecoraro M, Del Pizzo M, Marzocco S, et al. Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity. Toxicol Appl Pharmacol. 2016;293:44\u201352. https:\/\/doi.org\/10.1016\/j.taap.2016.01.006","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"7673_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12964-023-01077-5","volume":"21","author":"S Shi","year":"2023","unstructured":"Shi S, Chen Y, Luo Z, Nie G, Dai Y. Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy. Cell Commun Signal. 2023;21(1):61. https:\/\/doi.org\/10.1186\/s12964-023-01077-5","journal-title":"Cell Commun Signal"},{"issue":"23","key":"7673_CR30","doi-asserted-by":"publisher","first-page":"14649","DOI":"10.3390\/ijms232314649","volume":"23","author":"A Bhagat","year":"2022","unstructured":"Bhagat A, Shrestha P, Kleinerman ES. The innate immune system in cardiovascular diseases and its role in doxorubicin-induced cardiotoxicity. Int J Mol Sci. 2022;23(23):14649. https:\/\/doi.org\/10.3390\/ijms232314649","journal-title":"Int J Mol Sci"},{"issue":"3","key":"7673_CR31","doi-asserted-by":"publisher","first-page":"H459","DOI":"10.1152\/ajpheart.00401.2018","volume":"316","author":"PG Rodrigues","year":"2019","unstructured":"Rodrigues PG, Miranda-Silva D, Costa SM, et al. Early myocardial changes induced by doxorubicin in the nonfailing dilated ventricle. Am J Physiol Heart Circ Physiol. 2019;316(3):H459\u201375. https:\/\/doi.org\/10.1152\/ajpheart.00401.2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"7673_CR32","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12012-022-09721-1","volume":"22","author":"M Sheibani","year":"2022","unstructured":"Sheibani M, Azizi Y, Shayan M, Nezamoleslami S, Eslami F, Farjoo MH, Dehpour AR. Doxorubicin-induced cardiotoxicity: an overview on pre-clinical therapeutic approaches. Cardiovasc Toxicol. 2022;22(4):292\u2013310. https:\/\/doi.org\/10.1007\/s12012-022-09721-1","journal-title":"Cardiovasc Toxicol"},{"issue":"3","key":"7673_CR33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/CRD.0000000000000183","volume":"26","author":"DC Cole","year":"2018","unstructured":"Cole DC, Frishman WH. Cardiovascular complications of proteasome inhibitors used in multiple myeloma. Cardiol Rev. 2018;26(3):122\u20139. https:\/\/doi.org\/10.1097\/CRD.0000000000000183","journal-title":"Cardiol Rev"},{"issue":"3","key":"7673_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/jcu.23388","volume":"51","author":"D Mihalcea","year":"2023","unstructured":"Mihalcea D, Memis H, Balinisteanu A, et al. Myocardial work\u2014a new tool for early detection of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy induced-cardiotoxicity in hematological patients. J Clin Ultrasound. 2023;51(3):377\u201384. https:\/\/doi.org\/10.1002\/jcu.23388","journal-title":"J Clin Ultrasound"},{"key":"7673_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40959-019-0054-5","volume":"5","author":"N Bansal","year":"2019","unstructured":"Bansal N, Adams MJ, Ganatra S, et al. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardiooncology. 2019;5:18. https:\/\/doi.org\/10.1186\/s40959-019-0054-5","journal-title":"Cardiooncology"},{"issue":"1","key":"7673_CR36","doi-asserted-by":"publisher","first-page":"6653971","DOI":"10.1155\/2021\/6653971","volume":"2021","author":"\u0218 Sp\u00eenu","year":"2021","unstructured":"Sp\u00eenu \u0218, Cismaru G, Boarescu P-M, et al. ECG markers of cardiovascular toxicity in adult and pediatric cancer treatment. Dis Markers. 2021;2021(1):6653971. https:\/\/doi.org\/10.1155\/2021\/6653971","journal-title":"Dis Markers"},{"issue":"2","key":"7673_CR37","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ejhf.1631","volume":"22","author":"L Michel","year":"2020","unstructured":"Michel L, Mincu RI, Mahabadi AA, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020;22(2):350\u201361. https:\/\/doi.org\/10.1002\/ejhf.1631","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"7673_CR38","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jaccao.2024.02.004","volume":"6","author":"JN Upshaw","year":"2024","unstructured":"Upshaw JN, Parson SK, Buchsbaum RJ, et al. Dexrazoxane to prevent cardiotoxicity in adults treated with anthracyclines: JACC: CardioOncology controversies in cardio-oncology. JACC CardioOncol. 2024;6(2):322\u20134. https:\/\/doi.org\/10.1016\/j.jaccao.2024.02.004","journal-title":"JACC CardioOncol"},{"key":"7673_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.590226","volume":"8","author":"X Chen","year":"2020","unstructured":"Chen X, Yu C, Kang R, Tang D. Iron metabolism in ferroptosis. Front Cell Dev Biol. 2020;8:590226. https:\/\/doi.org\/10.3389\/fcell.2020.590226","journal-title":"Front Cell Dev Biol"},{"issue":"21","key":"7673_CR40","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1200\/jco.19.02856","volume":"38","author":"KD Getz","year":"2020","unstructured":"Getz KD, Sung L, Alonzo TA, et al. Effect of dexrazoxane on left ventricular systolic function and treatment outcomes in patients with acute myeloid leukemia: a report from the children\u2019s oncology group. J Clin Oncol. 2020;38(21):2398\u2013406. https:\/\/doi.org\/10.1200\/jco.19.02856","journal-title":"J Clin Oncol"},{"key":"7673_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.968534","volume":"9","author":"D He","year":"2022","unstructured":"He D, Hu J, Li Y, Zeng X. Preventive use of beta-blockers for anthracycline-induced cardiotoxicity: a network meta-analysis. Front Cardiovasc Med. 2022;9:968534. https:\/\/doi.org\/10.3389\/fcvm.2022.968534","journal-title":"Front Cardiovasc Med"},{"key":"7673_CR42","doi-asserted-by":"publisher","unstructured":"Al-Amir H, Janabi A, Hadi NR. Ameliorative effect of nebivolol in doxorubicin-induced cardiotoxicity. J Med Life. 2023;16(9):1357\u20131363. https:\/\/doi.org\/10.25122\/jml-2023-0090.","DOI":"10.25122\/jml-2023-0090"},{"key":"7673_CR43","doi-asserted-by":"publisher","unstructured":"Lee M, Chung WB, Lee Je, et al. Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. Cancer Med. 2021;10(12):3964\u20133973. https:\/\/doi.org\/10.1002\/cam4.3956","DOI":"10.1002\/cam4.3956"},{"issue":"9","key":"7673_CR44","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.3390\/biomedicines12091957","volume":"12","author":"I Belenichev","year":"2024","unstructured":"Belenichev I, Goncharov O, Bukhtiyarova N, et al. Beta-blockers of different generations: features of influence on the disturbances of myocardial energy metabolism in doxorubicin-induced chronic heart failure in rats. Biomedicines. 2024;12(9):1957. https:\/\/doi.org\/10.3390\/biomedicines12091957","journal-title":"Biomedicines"},{"issue":"1","key":"7673_CR45","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10741-020-09977-1","volume":"27","author":"P Sobczuk","year":"2022","unstructured":"Sobczuk P, Czerwi\u0144ska M, Kleibert M, Cudnoch-J\u0119drzejewska A. Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system\u2014from molecular mechanisms to therapeutic applications. Heart Fail Rev. 2022;27(1):295\u2013319. https:\/\/doi.org\/10.1007\/s10741-020-09977-1","journal-title":"Heart Fail Rev"},{"issue":"8","key":"7673_CR46","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/imj.16437","volume":"54","author":"S Lee","year":"2024","unstructured":"Lee S, Alsamarrai A, Xiao A, Wang TK. Prevention of anthracycline-t and trastuzumab induced decline in left ventricular ejection fraction with angiotensin-converting enzyme inhibitors or angiotensin receptor blocker: a narrative systematic review of randomised controlled trials. Intern Med J. 2024;54(8):1254\u201363. https:\/\/doi.org\/10.1111\/imj.16437","journal-title":"Intern Med J"},{"key":"7673_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131219","volume":"391","author":"D D\u2019Amario","year":"2023","unstructured":"D\u2019Amario D, Laborante R, Bianchini E, et al. Statins as preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized controlled trials. Int J Cardiol. 2023;391: 131219. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131219","journal-title":"Int J Cardiol"},{"issue":"10","key":"7673_CR48","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s11912-024-01579-6","volume":"26","author":"V Bhasin","year":"2024","unstructured":"Bhasin V, Vakilpour A, Scherrer-Crosbie M. Statins for the primary prevention of anthracycline cardiotoxicity: a comprehensive review. Curr Oncol Rep. 2024;26(10):1197\u2013204. https:\/\/doi.org\/10.1007\/s11912-024-01579-6","journal-title":"Curr Oncol Rep"},{"key":"7673_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100874","volume":"20","author":"M Karamat","year":"2024","unstructured":"Karamat M, Hussain B, Ahmed MM, et al. Deciphering the cardioprotective effects of statins in anthracycline-related cardiac dysfunction: a systematic review and meta-analysis. Am J Prev Cardiol. 2024;20: 100874. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100874","journal-title":"Am J Prev Cardiol"},{"key":"7673_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2022.104818","volume":"127","author":"T Chunchai","year":"2022","unstructured":"Chunchai T, Arinno A, Ongnok B, et al. Ranolazine alleviated cardiac\/brain dysfunction in doxorubicin-treated rats. Exp Mol Pathol. 2022;127: 104818. https:\/\/doi.org\/10.1016\/j.yexmp.2022.104818","journal-title":"Exp Mol Pathol"},{"issue":"2","key":"7673_CR51","doi-asserted-by":"publisher","first-page":"66","DOI":"10.5301\/heartint.5000219","volume":"9","author":"GL Murray","year":"2014","unstructured":"Murray GL, Colombo J. Ranolazine preserves and improves left ventricular ejection fraction and autonomic measures when added to guideline-driven therapy in chronic heart failure. Heart Int. 2014;9(2):66\u201373. https:\/\/doi.org\/10.5301\/heartint.5000219","journal-title":"Heart Int"},{"issue":"3","key":"7673_CR52","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1016\/s1470-2045(23)00012-8","volume":"24","author":"MJ Ehrhardt","year":"2023","unstructured":"Ehrhardt MJ, Leerink JM, Mulder RL, et al. Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2023;24(3):e108\u201320. https:\/\/doi.org\/10.1016\/s1470-2045(23)00012-8","journal-title":"Lancet Oncol"},{"issue":"24","key":"7673_CR53","doi-asserted-by":"publisher","first-page":"00036","DOI":"10.1016\/j.tcm.2024.04.004","volume":"S1050\u20131738","author":"JSK Chan","year":"2024","unstructured":"Chan JSK, Chan RNC, Lee YHA, et al. Cardiovascular health of patients with cancer: challenges abound. Trends Cardiovasc Med. 2024;S1050\u20131738(24):00036\u20137. https:\/\/doi.org\/10.1016\/j.tcm.2024.04.004","journal-title":"Trends Cardiovasc Med"},{"issue":"4","key":"7673_CR54","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.37308","volume":"15","author":"P Rahimi","year":"2023","unstructured":"Rahimi P, Barootkoob B, ElHashash A, Nair A. Efficacy of dexrazoxane in cardiac protection in pediatric patients treated with anthracyclines. Cureus. 2023;15(4): e37308. https:\/\/doi.org\/10.7759\/cureus.37308","journal-title":"Cureus"},{"issue":"2","key":"7673_CR55","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1470-2045(23)00637-X","volume":"25","author":"SH Armenian","year":"2024","unstructured":"Armenian SH, Hudson MM, Lindenfeld L, et al. Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial. Lancet Oncol. 2024;25(2):235\u201345. https:\/\/doi.org\/10.1016\/S1470-2045(23)00637-X","journal-title":"Lancet Oncol"},{"issue":"1","key":"7673_CR56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","volume":"4","author":"T Omland","year":"2022","unstructured":"Omland T, Heck SL, Gulati G. The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2022;4(1):19\u201337. https:\/\/doi.org\/10.1016\/j.jaccao.2022.01.101","journal-title":"JACC CardioOncol"},{"issue":"3","key":"7673_CR57","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1177\/10781552221147660","volume":"29","author":"I Moustafa","year":"2023","unstructured":"Moustafa I, Viljoen M, Perumal-Pillay VA, Oosthuizen F. Critical appraisal of clinical guidelines for prevention and management of doxorubicin-induced cardiotoxicity. J Oncol Pharm Pract. 2023;29(3):695\u2013708. https:\/\/doi.org\/10.1177\/10781552221147660","journal-title":"J Oncol Pharm Pract"},{"key":"7673_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.907266","volume":"9","author":"NF Sangweni","year":"2022","unstructured":"Sangweni NF, van Vuuren D, Mabasa L, et al. Prevention of anthracycline-induced cardiotoxicity: the good and bad of current and alternative therapies. Front Cardiovasc Med. 2022;9:907266. https:\/\/doi.org\/10.3389\/fcvm.2022.907266","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"7673_CR59","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s11897-017-0347-7","volume":"14","author":"A Dietl","year":"2017","unstructured":"Dietl A, Maack C. Targeting mitochondrial calcium handling and reactive oxygen species in heart failure. Curr Heart Fail Rep. 2017;14(4):338\u201349. https:\/\/doi.org\/10.1007\/s11897-017-0347-7","journal-title":"Curr Heart Fail Rep"},{"issue":"2","key":"7673_CR60","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jjcc.2022.01.001","volume":"80","author":"K Shinlapawittayatorn","year":"2022","unstructured":"Shinlapawittayatorn K, Chattipakorn SC, Chattipakorn N. The effects of doxorubicin on cardiac calcium homeostasis and contractile function. J Cardiol. 2022;80(2):125\u201332. https:\/\/doi.org\/10.1016\/j.jjcc.2022.01.001","journal-title":"J Cardiol"},{"issue":"4","key":"7673_CR61","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1124\/mol.114.093849","volume":"86","author":"AD Hanna","year":"2014","unstructured":"Hanna AD, Lam A, Tham S, Dulhunty AF, Beard NA. Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A. Mol Pharmacol. 2014;86(4):438\u201349. https:\/\/doi.org\/10.1124\/mol.114.093849","journal-title":"Mol Pharmacol"},{"issue":"1","key":"7673_CR62","doi-asserted-by":"publisher","first-page":"7176282","DOI":"10.1155\/2022\/7176282","volume":"2022","author":"G Ling","year":"2022","unstructured":"Ling G, Wang X, Tan N, et al. Mechanisms and drug intervention for doxorubicin-induced cardiotoxicity based on mitochondrial bioenergetics. Oxid Med Cell Longev. 2022;2022(1):7176282. https:\/\/doi.org\/10.1155\/2022\/7176282","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"7673_CR63","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.3390\/ijms24065564","volume":"24","author":"M Waseem","year":"2023","unstructured":"Waseem M, Wang B-D. Promising strategy of mPTP modulation in cancer therapy: an emerging progress and future insight. Int J Mol Sci. 2023;24(6):5564. https:\/\/doi.org\/10.3390\/ijms24065564.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7673_CR64","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.bbrc.2015.02.004","volume":"460","author":"J Krebs","year":"2015","unstructured":"Krebs J, Agellon LB, Michalak M. Ca2+ homeostasis and endoplasmic reticulum (ER) stress: an integrated view of calcium signaling. Biochem Biophys Res Commun. 2015;460(1):114\u201321. https:\/\/doi.org\/10.1016\/j.bbrc.2015.02.004","journal-title":"Biochem Biophys Res Commun"},{"key":"7673_CR65","doi-asserted-by":"publisher","unstructured":"Senft D, Ze\u2019ev AR. UPR, autophagy, and mitochondria crosstalk underlies the ER stress response. Trends Biochem Sci. 2015;40(3):141\u20138. https:\/\/doi.org\/10.1016\/j.tibs.2015.01.002","DOI":"10.1016\/j.tibs.2015.01.002"},{"key":"7673_CR66","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ceca.2017.05.003","volume":"69","author":"S Marchi","year":"2018","unstructured":"Marchi S, Patergnani S, Missiroli S, et al. Mitochondrial and endoplasmic reticulum calcium homeostasis and cell death. Cell Calcium. 2018;69:62\u201372. https:\/\/doi.org\/10.1016\/j.ceca.2017.05.003","journal-title":"Cell Calcium"},{"issue":"3","key":"7673_CR67","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/cdd.2014.143","volume":"22","author":"Y Liu","year":"2015","unstructured":"Liu Y, Levine B. Autosis and autophagic cell death: the dark side of autophagy. Cell Death Differ. 2015;22(3):367\u201376. https:\/\/doi.org\/10.1038\/cdd.2014.143","journal-title":"Cell Death Differ"},{"issue":"36","key":"7673_CR68","doi-asserted-by":"publisher","first-page":"11389","DOI":"10.1073\/pnas.1513047112","volume":"112","author":"G Santulli","year":"2015","unstructured":"Santulli G, Xie W, Reiken SR, Marks AR. Mitochondrial calcium overload is a key determinant in heart failure. Proc Natl Acad Sci U S A. 2015;112(36):11389\u201394. https:\/\/doi.org\/10.1073\/pnas.1513047112","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"7673_CR69","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/cells11010096","volume":"11","author":"M Pitsch","year":"2021","unstructured":"Pitsch M, Kant S, Mytzka C, Leube RE, Krusche CA. Autophagy and endoplasmic reticulum stress during onset and progression of arrhythmogenic cardiomyopathy. Cells. 2021;11(1):96. https:\/\/doi.org\/10.3390\/cells11010096","journal-title":"Cells"},{"key":"7673_CR70","doi-asserted-by":"publisher","unstructured":"Xu H-x, Cui S-m, Zhang Y-m, Ren J. Mitochondrial Ca2+ regulation in the etiology of heart failure: physiological and pathophysiological implications. Acta Pharmacol Sin. 2020;41(10):1301\u20131309. https:\/\/doi.org\/10.1038\/s41401-020-0476-5","DOI":"10.1038\/s41401-020-0476-5"},{"key":"7673_CR71","doi-asserted-by":"publisher","unstructured":"Dia M, Gomez L, Thibault H, et al. Reduced reticulum\u2013mitochondria Ca 2+ transfer is an early and reversible trigger of mitochondrial dysfunctions in diabetic cardiomyopathy. Basic Res Cardiol. 2020 30;115(6):74. https:\/\/doi.org\/10.1007\/s00395-020-00835-7.","DOI":"10.1007\/s00395-020-00835-7"},{"key":"7673_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.822969","volume":"8","author":"D Yang","year":"2021","unstructured":"Yang D, Liu HQ, Liu FY, et al. Mitochondria in pathological cardiac hypertrophy research and therapy. Front Cardiovasc Med. 2021;8: 822969. https:\/\/doi.org\/10.3389\/fcvm.2021.822969","journal-title":"Front Cardiovasc Med"},{"key":"7673_CR73","doi-asserted-by":"publisher","first-page":"1015722","DOI":"10.3389\/fcvm.2022.1015722","volume":"9","author":"Y Luan","year":"2022","unstructured":"Luan Y, Jin Y, Zhang P, Li H, Yang Y. Mitochondria-associated endoplasmic reticulum membranes and cardiac hypertrophy: molecular mechanisms and therapeutic targets. Front Cardiovasc Med. 2022;9:1015722. https:\/\/doi.org\/10.3389\/fcvm.2022.1015722","journal-title":"Front Cardiovasc Med"},{"issue":"13","key":"7673_CR74","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/eurheartj\/ehad028","volume":"44","author":"EE Nollet","year":"2023","unstructured":"Nollet EE, Duursma I, Rozenbaum A, et al. Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration. Eur Heart J. 2023;44(13):1170\u201385. https:\/\/doi.org\/10.1093\/eurheartj\/ehad028","journal-title":"Eur Heart J"},{"issue":"19","key":"7673_CR75","doi-asserted-by":"publisher","first-page":"14845","DOI":"10.3390\/ijms241914845","volume":"24","author":"M Schlittler","year":"2023","unstructured":"Schlittler M, Pramstaller PP, Rossini A, De Bortoli M. Myocardial fibrosis in hypertrophic cardiomyopathy: a perspective from fibroblasts. Int J Mol Sci. 2023;24(19):14845. https:\/\/doi.org\/10.3390\/ijms241914845","journal-title":"Int J Mol Sci"},{"issue":"4","key":"7673_CR76","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/ejhf.1421","volume":"21","author":"A Piek","year":"2019","unstructured":"Piek A, Sillj\u00e9 HHW, de Boer RA. The vicious cycle of arrhythmia and myocardial fibrosis. Eur J Heart Fail. 2019;21(4):492\u20134. https:\/\/doi.org\/10.1002\/ejhf.1421","journal-title":"Eur J Heart Fail"},{"key":"7673_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.715258","volume":"8","author":"W Jiang","year":"2021","unstructured":"Jiang W, Xiong Y, Li X, Yang Y. Cardiac fibrosis: cellular effectors, molecular pathways, and exosomal roles. Front Cardiovasc Med. 2021;8:715258. https:\/\/doi.org\/10.3389\/fcvm.2021.715258","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"7673_CR78","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/s44161-022-00118-5","volume":"1","author":"A Yoshii","year":"2022","unstructured":"Yoshii A, Tian R. Deciphering metabolic remodeling of the failing hearts. Nat Cardiovasc Res. 2022;1(9):800\u20131. https:\/\/doi.org\/10.1038\/s44161-022-00118-5","journal-title":"Nat Cardiovasc Res"},{"key":"7673_CR79","doi-asserted-by":"publisher","first-page":"1323760","DOI":"10.3389\/fcvm.2023.1323760","volume":"10","author":"N D\u00f6rmann","year":"2024","unstructured":"D\u00f6rmann N, Hammer E, Struckmann K, et al. Metabolic remodeling in cardiac hypertrophy and heart failure with reduced ejection fraction occurs independent of transcription factor EB in mice. Front Cardiovasc Med. 2024;10:1323760. https:\/\/doi.org\/10.3389\/fcvm.2023.1323760","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"7673_CR80","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3390\/molecules23051184","volume":"23","author":"R Zilinyi","year":"2018","unstructured":"Zilinyi R, Czompa A, Czegledi A, et al. The cardioprotective effect of metformin in doxorubicin-induced cardiotoxicity: the role of autophagy. Molecules. 2018;23(5):1184. https:\/\/doi.org\/10.3390\/molecules23051184","journal-title":"Molecules"},{"issue":"13","key":"7673_CR81","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.3390\/cells11132000","volume":"11","author":"L Schirone","year":"2022","unstructured":"Schirone L, D\u2019Ambrosio L, Forte M, et al. Mitochondria and doxorubicin-induced cardiomyopathy: a complex interplay. Cells. 2022;11(13):2000. https:\/\/doi.org\/10.3390\/cells11132000","journal-title":"Cells"},{"key":"7673_CR82","unstructured":"Yang Y, Zhang H, Li X, Yang T, Jiang Q. Effects of PPAR\u03b1\/PGC-1\u03b1 on the myocardial energy metabolism during heart failure in the doxorubicin induced dilated cardiomyopathy in mice. Int J Clin Exp Med. 2014;7(9):2435. eCollection 2014."},{"issue":"6","key":"7673_CR83","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.gendis.2020.12.006","volume":"8","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Xu H, Yan L, et al. PGC-1\u03b1 promotes mitochondrial respiration and biogenesis during the differentiation of hiPSCs into cardiomyocytes. Genes Dis. 2020;8(6):891\u2013906. https:\/\/doi.org\/10.1016\/j.gendis.2020.12.006","journal-title":"Genes Dis"},{"key":"7673_CR84","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejphar.2014.05.017","volume":"737","author":"J Guo","year":"2014","unstructured":"Guo J, Guo Q, Fang H, et al. Cardioprotection against doxorubicin by metallothionein Is associated with preservation of mitochondrial biogenesis involving PGC-1\u03b1 pathway. Eur J Pharmacol. 2014;737:117\u201324. https:\/\/doi.org\/10.1016\/j.ejphar.2014.05.017","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"7673_CR85","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/toxres\/tfad007","volume":"12","author":"M Chen","year":"2023","unstructured":"Chen M. Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK\/SIRT-1\/PGC-1\u03b1-mediated mitochondrial biogenesis. Toxicol Res. 2023;12(2):216\u201323. https:\/\/doi.org\/10.1093\/toxres\/tfad007","journal-title":"Toxicol Res"},{"key":"7673_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.773834","volume":"12","author":"W Li","year":"2021","unstructured":"Li W, Cao J, Wang X, et al. Ferruginol restores SIRT1-PGC-1\u03b1-mediated mitochondrial biogenesis and fatty acid oxidation for the treatment of DOX-induced cardiotoxicity. Front Pharmacol. 2021;12: 773834. https:\/\/doi.org\/10.3389\/fphar.2021.773834","journal-title":"Front Pharmacol"},{"issue":"2","key":"7673_CR87","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00580-019-03077-9","volume":"29","author":"P Zare","year":"2020","unstructured":"Zare P, Moghadaszadeh M, Asadi M, Ebadi F, Badalzadeh R. Effect of high-intensity interval training on expression of microRNA-149 and genes regulating mitochondrial biogenesis in doxorubicin-cardiotoxicity in rats. Comp Clin Path. 2020;29(2):425\u201331. https:\/\/doi.org\/10.1007\/s00580-019-03077-9","journal-title":"Comp Clin Path"},{"issue":"7","key":"7673_CR88","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00210-020-01818-0","volume":"393","author":"S Babaei-Kouchaki","year":"2020","unstructured":"Babaei-Kouchaki S, Babapour V, Panahi N, Badalzadeh R. Effect of troxerutin on oxidative stress and expression of genes regulating mitochondrial biogenesis in doxorubicin-induced myocardial injury in rats. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(7):1187\u201395. https:\/\/doi.org\/10.1007\/s00210-020-01818-0","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"2","key":"7673_CR89","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/toxsci\/kfw006","volume":"150","author":"H Yuan","year":"2016","unstructured":"Yuan H, Zhang Q, Guo J, et al. A PGC-1\u03b1-mediated transcriptional network maintains mitochondrial redox and bioenergetic homeostasis against doxorubicin-induced toxicity in human cardiomyocytes: implementation of TT21C. Toxicol Sci. 2016;150(2):400\u201317. https:\/\/doi.org\/10.1093\/toxsci\/kfw006","journal-title":"Toxicol Sci"},{"issue":"11","key":"7673_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.528267","volume":"8","author":"W Wang","year":"2020","unstructured":"Wang W, Fang Q, Zhang Z, et al. PPAR\u03b1 ameliorates doxorubicin-induced cardiotoxicity by reducing mitochondria-dependent apoptosis via regulating MEOX1. Front Pharmacol. 2020;8(11): 528267. https:\/\/doi.org\/10.3389\/fphar.2020.528267","journal-title":"Front Pharmacol"},{"issue":"1","key":"7673_CR91","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1146\/annurev.physiol.010908.163111","volume":"72","author":"RS Whelan","year":"2010","unstructured":"Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol. 2010;72(1):19\u201344. https:\/\/doi.org\/10.1146\/annurev.physiol.010908.163111","journal-title":"Annu Rev Physiol"},{"issue":"2","key":"7673_CR92","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10741-016-9533-z","volume":"21","author":"A Briasoulis","year":"2016","unstructured":"Briasoulis A, Androulakis E, Christophides T, Tousoulis D. The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Fail Rev. 2016;21(2):169\u201376. https:\/\/doi.org\/10.1007\/s10741-016-9533-z","journal-title":"Heart Fail Rev"},{"issue":"7","key":"7673_CR93","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1161\/CIRCRESAHA.119.314681","volume":"126","author":"KB Wallace","year":"2020","unstructured":"Wallace KB, Sard\u00e3o VA, Oliveira PJ. Mitochondrial determinants of doxorubicin-induced cardiomyopathy. Circ Res. 2020;126(7):926\u201341. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.314681","journal-title":"Circ Res"},{"issue":"4","key":"7673_CR94","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/03009858211005537","volume":"58","author":"SF Santagostino","year":"2021","unstructured":"Santagostino SF, Assenmacher C-A, Tarrant JC, Adedeji AO, Radaelli E. Mechanisms of regulated cell death: current perspectives. Vet Pathol. 2021;58(4):596\u2013623. https:\/\/doi.org\/10.1177\/03009858211005537","journal-title":"Vet Pathol"},{"key":"7673_CR95","doi-asserted-by":"publisher","first-page":"44735","DOI":"10.1038\/srep44735","volume":"7","author":"L Zhao","year":"2017","unstructured":"Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017;7:44735. https:\/\/doi.org\/10.1038\/srep44735","journal-title":"Sci Rep"},{"key":"7673_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2019.100709","volume":"21","author":"JH Doroshow","year":"2019","unstructured":"Doroshow JH, Esworthy RS, Chu F-F. Control of doxorubicin-induced, reactive oxygen-related apoptosis by glutathione peroxidase 1 in cardiac fibroblasts. Biochem Biophys Rep. 2019;21:100709. https:\/\/doi.org\/10.1016\/j.bbrep.2019.100709","journal-title":"Biochem Biophys Rep"},{"key":"7673_CR97","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.yjmcc.2015.12.010","volume":"90","author":"Z Sun","year":"2016","unstructured":"Sun Z, Schriewer J, Tang M, et al. The TGF-\u03b2 pathway mediates doxorubicin effects on cardiac endothelial cells. J Mol Cell Cardiol. 2016;90:129\u201338. https:\/\/doi.org\/10.1016\/j.yjmcc.2015.12.010","journal-title":"J Mol Cell Cardiol"},{"key":"7673_CR98","doi-asserted-by":"publisher","unstructured":"Lee PJ, Rudenko D, Kuliszewski MA, et al. Survivin gene therapy attenuates left ventricular systolic dysfunction in doxorubicin cardiomyopathy by reducing apoptosis and fibrosis. Cardiovasc Res. 2014 1;101(3):423\u201333. https:\/\/doi.org\/10.1093\/cvr\/cvu001","DOI":"10.1093\/cvr\/cvu001"},{"issue":"9","key":"7673_CR99","doi-asserted-by":"publisher","first-page":"H1453","DOI":"10.1152\/ajpheart.00554.2015","volume":"309","author":"ZV Varga","year":"2015","unstructured":"Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015;309(9):H1453\u201367. https:\/\/doi.org\/10.1152\/ajpheart.00554.2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"7673_CR100","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.bbrc.2006.05.059","volume":"345","author":"G Bajaj","year":"2006","unstructured":"Bajaj G, Sharma RK. TNF-\u03b1-mediated cardiomyocyte apoptosis involves caspase-12 and calpain. Biochem Biophys Res Commun. 2006;345(4):1558\u201364. https:\/\/doi.org\/10.1016\/j.bbrc.2006.05.059","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"7673_CR101","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005357","volume":"6","author":"F Sun","year":"2017","unstructured":"Sun F, Li X, Duan WQ, et al. Transforming growth factor-\u03b2 receptor III is a potential regulator of ischemia-induced cardiomyocyte apoptosis. J Am Heart Assoc. 2017;6(6):e005357. https:\/\/doi.org\/10.1161\/JAHA.116.005357","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"7673_CR102","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11897-020-00489-5","volume":"17","author":"EL Robinson","year":"2020","unstructured":"Robinson EL, Azodi M, Heymans S, Heggermont W. Anthracycline-related heart failure: certain knowledge and open questions. Curr Heart Fail Rep. 2020;17(6):357\u201364. https:\/\/doi.org\/10.1007\/s11897-020-00489-5","journal-title":"Curr Heart Fail Rep"},{"key":"7673_CR103","doi-asserted-by":"publisher","unstructured":"Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98(12):2854\u201365. https:\/\/doi.org\/10.1172\/jci119114.","DOI":"10.1172\/jci119114"},{"key":"7673_CR104","doi-asserted-by":"publisher","first-page":"1256852","DOI":"10.3389\/fphys.2023.1256852","volume":"14","author":"LA Grisanti","year":"2023","unstructured":"Grisanti LA. TRAIL and its receptors in cardiac diseases. Front Physiol. 2023;14:1256852. https:\/\/doi.org\/10.3389\/fphys.2023.1256852.","journal-title":"Front Physiol"},{"issue":"6","key":"7673_CR105","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1006\/jmcc.2000.1132","volume":"32","author":"M Yamaoka","year":"2000","unstructured":"Yamaoka M, Yamaguchi S, Suzuki T, et al. Apoptosis in rat cardiac myocytes induced by Fas ligand: priming for Fas-mediated apoptosis with doxorubicin. J Mol Cell Cardiol. 2000;32(6):881\u20139. https:\/\/doi.org\/10.1006\/jmcc.2000.1132","journal-title":"J Mol Cell Cardiol"},{"issue":"4","key":"7673_CR106","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/1440-1681.13225","volume":"47","author":"AA Shati","year":"2020","unstructured":"Shati AA. Doxorubicin-induces NFAT\/Fas\/FasL cardiac apoptosis in rats through activation of calcineurin and P38 MAPK and inhibition of mTOR signalling pathways. Clin Exp Pharmacol Physiol. 2020;47(4):660\u201376. https:\/\/doi.org\/10.1111\/1440-1681.13225","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"7673_CR107","doi-asserted-by":"publisher","first-page":"1075917","DOI":"10.3389\/fcell.2023.1075917","volume":"11","author":"X Yu","year":"2023","unstructured":"Yu X, Yang Y, Chen T, et al. Cell death regulation in myocardial toxicity induced by antineoplastic drugs. Front Cell Dev Biol. 2023;11:1075917. https:\/\/doi.org\/10.3389\/fcell.2023.1075917","journal-title":"Front Cell Dev Biol"},{"key":"7673_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117570","volume":"250","author":"B Farhood","year":"2020","unstructured":"Farhood B, Ashrafizadeh M, Hoseini-Ghahfarokhi M, et al. Targeting of cellular redox metabolism for mitigation of radiation injury. Life Sci. 2020;250: 117570. https:\/\/doi.org\/10.1016\/j.lfs.2020.117570","journal-title":"Life Sci"},{"issue":"48","key":"7673_CR109","doi-asserted-by":"publisher","first-page":"11817","DOI":"10.1021\/jf404092f","volume":"61","author":"W-C Chen","year":"2013","unstructured":"Chen W-C, Lai Y-A, Lin Y-C, et al. Curcumin suppresses doxorubicin-induced epithelial\u2013mesenchymal transition via the inhibition of TGF-\u03b2 and PI3K\/AKT signaling pathways in triple-negative breast Cancer cells. J Agric Food Chem. 2013;61(48):11817\u201324. https:\/\/doi.org\/10.1021\/jf404092f","journal-title":"J Agric Food Chem"},{"issue":"4","key":"7673_CR110","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41569-021-00624-2","volume":"19","author":"M Mehdizadeh","year":"2022","unstructured":"Mehdizadeh M, Aguilar M, Thorin E, Ferbeyre G, Nattel S. The role of cellular senescence in cardiac disease: basic biology and clinical relevance. Nat Rev Cardiol. 2022;19(4):250\u201364. https:\/\/doi.org\/10.1038\/s41569-021-00624-2","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"7673_CR111","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1152\/physrev.00007.2022","volume":"103","author":"K Evangelou","year":"2023","unstructured":"Evangelou K, Vasileiou PVS, Papaspyropoulos A, et al. Cellular senescence and cardiovascular diseases: moving to the \u201cheart\u201d of the problem. Physiol Rev. 2023;103(1):609\u201347. https:\/\/doi.org\/10.1152\/physrev.00007.2022","journal-title":"Physiol Rev"},{"issue":"5","key":"7673_CR112","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/cvr\/cvab161","volume":"118","author":"MS Chen","year":"2022","unstructured":"Chen MS, Lee RT, Garbern JC. Senescence mechanisms and targets in the heart. Cardiovasc Res. 2022;118(5):1173\u201387. https:\/\/doi.org\/10.1093\/cvr\/cvab161","journal-title":"Cardiovasc Res"},{"key":"7673_CR113","doi-asserted-by":"publisher","unstructured":"Huang P, Bai L, Liu L, et al. Redd1 knockdown prevents doxorubicin-induced cardiac senescence. Aging. 2021;13(10):13788\u2013806. https:\/\/doi.org\/10.18632\/aging.202972","DOI":"10.18632\/aging.202972"},{"issue":"1","key":"7673_CR114","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41420-023-01792-5","volume":"10","author":"Y Luan","year":"2024","unstructured":"Luan Y, Zhu X, Jiao Y, et al. Cardiac cell senescence: molecular mechanisms, key proteins and therapeutic targets. Cell Death Discov. 2024;10(1):78. https:\/\/doi.org\/10.1038\/s41420-023-01792-5","journal-title":"Cell Death Discov"},{"issue":"2","key":"7673_CR115","doi-asserted-by":"publisher","first-page":"C380","DOI":"10.1152\/ajpcell.00073.2019","volume":"318","author":"MA Mitry","year":"2020","unstructured":"Mitry MA, Laurent D, Keith BL, et al. Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity. Am J Physiol Cell Physiol. 2020;318(2):C380\u201391. https:\/\/doi.org\/10.1152\/ajpcell.00073.2019","journal-title":"Am J Physiol Cell Physiol"},{"issue":"18","key":"7673_CR116","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1111\/febs.17164","volume":"291","author":"W Xia","year":"2024","unstructured":"Xia W, Chen H, Yang H, et al. Depletion of SASP senescent cardiomyocytes with senolytic drugs confers therapeutic effects in doxorubicin-related cardiotoxicity. FEBS J. 2024;291(18):4029\u201342. https:\/\/doi.org\/10.1111\/febs.17164","journal-title":"FEBS J"},{"key":"7673_CR117","doi-asserted-by":"publisher","unstructured":"Xia W, Chang B, Li L, et al. MicroRNA therapy confers anti-senescent effects on doxorubicin-related cardiotoxicity by intracellular and paracrine signaling. Aging. 2021;13(23):25256\u201370. https:\/\/doi.org\/10.18632\/aging.203743","DOI":"10.18632\/aging.203743"},{"issue":"9","key":"7673_CR118","doi-asserted-by":"publisher","first-page":"8290","DOI":"10.1074\/jbc.M308033200","volume":"279","author":"CC Lim","year":"2004","unstructured":"Lim CC, Zuppinger C, Guo X, et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem. 2004;279(9):8290\u20139. https:\/\/doi.org\/10.1074\/jbc.M308033200","journal-title":"J Biol Chem"},{"issue":"6","key":"7673_CR119","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1078\/0171-9335-00171","volume":"80","author":"A Mailloux","year":"2001","unstructured":"Mailloux A, Grenet K, Bruneel A, et al. Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis. Eur J Cell Biol. 2001;80(6):442\u20139. https:\/\/doi.org\/10.1078\/0171-9335-00171","journal-title":"Eur J Cell Biol"},{"issue":"307","key":"7673_CR120","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.toxlet.2019.02.013","volume":"1","author":"M Songbo","year":"2019","unstructured":"Songbo M, Lang H, Xinyong C, et al. Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol Lett. 2019;1(307):41\u20138. https:\/\/doi.org\/10.1016\/j.toxlet.2019.02.013","journal-title":"Toxicol Lett"},{"issue":"1","key":"7673_CR121","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/med.21280","volume":"34","author":"FS Carvalho","year":"2014","unstructured":"Carvalho FS, Burgeiro A, Garcia R, et al. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev. 2014;34(1):106\u201335. https:\/\/doi.org\/10.1002\/med.21280","journal-title":"Med Res Rev"},{"issue":"9\u201310","key":"7673_CR122","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10495-022-01760-x","volume":"27","author":"LN Maslov","year":"2022","unstructured":"Maslov LN, Popov SV, Naryzhnaya NV, et al. The regulation of necroptosis and perspectives for the development of new drugs preventing ischemic\/reperfusion of cardiac injury. Apoptosis. 2022;27(9\u201310):697\u2013719. https:\/\/doi.org\/10.1007\/s10495-022-01760-x","journal-title":"Apoptosis"},{"key":"7673_CR123","doi-asserted-by":"publisher","unstructured":"Moriwaki K, Bertin J, Gough P, Orlowski G, Chan FK. Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death. Cell Death Dis. 2015 12;6(2):e1636. https:\/\/doi.org\/10.1038\/cddis.2015.16","DOI":"10.1038\/cddis.2015.16"},{"key":"7673_CR124","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s42003-017-0007-1","volume":"1","author":"K Weber","year":"2018","unstructured":"Weber K, Roelandt R, Bruggeman I, Estornes Y, Vandenabeele P. Nuclear RIPK3 and MLKL contribute to cytosolic necrosome formation and necroptosis. Commun Biol. 2018;1:6. https:\/\/doi.org\/10.1038\/s42003-017-0007-1","journal-title":"Commun Biol"},{"issue":"51","key":"7673_CR125","doi-asserted-by":"publisher","first-page":"E5537","DOI":"10.1073\/pnas.1414665111","volume":"111","author":"R Dhingra","year":"2014","unstructured":"Dhingra R, Margulets V, Chowdhury SR, et al. Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling. Proc Natl Acad Sci U S A. 2014;111(51):E5537\u201344. https:\/\/doi.org\/10.1073\/pnas.1414665111","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5\u20136","key":"7673_CR126","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10495-022-01721-4","volume":"27","author":"J Huang","year":"2022","unstructured":"Huang J, Chang Z, Lu Q, Chen X, Najafi M. Nobiletin as an inducer of programmed cell death in cancer: a review. Apoptosis. 2022;27(5\u20136):297\u2013310. https:\/\/doi.org\/10.1007\/s10495-022-01721-4","journal-title":"Apoptosis"},{"key":"7673_CR127","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s12012-020-09576-4","volume":"20","author":"S Wei","year":"2020","unstructured":"Wei S, Ma W, Li X, et al. Involvement of ROS\/NLRP3 inflammasome signaling pathway in doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol. 2020;20:507\u201319. https:\/\/doi.org\/10.1007\/s12012-020-09576-4","journal-title":"Cardiovasc Toxicol"},{"key":"7673_CR128","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.trsl.2022.05.001","volume":"248","author":"B Ye","year":"2022","unstructured":"Ye B, Shi X, Xu J, et al. Gasdermin D mediates doxorubicin-induced cardiomyocyte pyroptosis and cardiotoxicity via directly binding to doxorubicin and changes in mitochondrial damage. Transl Res. 2022;248:36\u201350. https:\/\/doi.org\/10.1016\/j.trsl.2022.05.001","journal-title":"Transl Res"},{"key":"7673_CR129","doi-asserted-by":"publisher","first-page":"4938287","DOI":"10.1155\/2023\/4938287","volume":"2023","author":"Z Ping","year":"2023","unstructured":"Ping Z, Fangfang T, Yuliang Z, et al. Oxidative stress and pyroptosis in doxorubicin-induced heart failure and atrial fibrillation. Oxid Med Cell Longev. 2023;2023:4938287. https:\/\/doi.org\/10.1155\/2023\/4938287.","journal-title":"Oxid Med Cell Longev"},{"key":"7673_CR130","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.132747","volume":"5","author":"T Tadokoro","year":"2020","unstructured":"Tadokoro T, Ikeda M, Ide T, et al. Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight. 2020;5:e132747. https:\/\/doi.org\/10.1172\/jci.insight.132747","journal-title":"JCI Insight"},{"issue":"8","key":"7673_CR131","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.bbagen.2017.05.019","volume":"1861","author":"GO Latunde-Dada","year":"2017","unstructured":"Latunde-Dada GO. Ferroptosis: role of lipid peroxidation, iron and ferritinophagy. Biochim Biophys Acta Gen Subj. 2017;1861(8):1893\u2013900. https:\/\/doi.org\/10.1016\/j.bbagen.2017.05.019","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"7673_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102021","volume":"45","author":"S Jang","year":"2021","unstructured":"Jang S, Chapa-Dubocq XR, Tyurina YY, et al. Elucidating the contribution of mitochondrial glutathione to ferroptosis in cardiomyocytes. Redox Biol. 2021;45:102021. https:\/\/doi.org\/10.1016\/j.redox.2021.102021","journal-title":"Redox Biol"},{"issue":"1","key":"7673_CR133","doi-asserted-by":"publisher","first-page":"H156","DOI":"10.1152\/ajpheart.00076.2019","volume":"317","author":"A Stamenkovic","year":"2019","unstructured":"Stamenkovic A, Pierce GN, Ravandi A. Phospholipid oxidation products in ferroptotic myocardial cell death. Am J Physiol Heart Circ Physiol. 2019;317(1):H156\u201363. https:\/\/doi.org\/10.1152\/ajpheart.00076.2019","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"8","key":"7673_CR134","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jacbts.2020.04.014","volume":"5","author":"J Nah","year":"2020","unstructured":"Nah J, Zablocki D, Sadoshima J. Autosis: a new target to prevent cell death. JACC Basic Transl Sci. 2020;5(8):857\u201369. https:\/\/doi.org\/10.1016\/j.jacbts.2020.04.014","journal-title":"JACC Basic Transl Sci"},{"key":"7673_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yjmcc.2017.01.007","volume":"104","author":"JJ Bartlett","year":"2017","unstructured":"Bartlett JJ, Trivedi PC, Pulinilkunnil T. Autophagic dysregulation in doxorubicin cardiomyopathy. J Mol Cell Cardiol. 2017;104:1\u20138. https:\/\/doi.org\/10.1016\/j.yjmcc.2017.01.007","journal-title":"J Mol Cell Cardiol"},{"issue":"17","key":"7673_CR136","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1161\/CIRCULATIONAHA.115.017443","volume":"133","author":"DL Li","year":"2016","unstructured":"Li DL, Wang ZV, Ding G, et al. Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification. Circulation. 2016;133(17):1668\u201387. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.017443","journal-title":"Circulation"},{"key":"7673_CR137","doi-asserted-by":"publisher","first-page":"9926635","DOI":"10.1155\/2022\/9926635","volume":"2022","author":"Y Qin","year":"2022","unstructured":"Qin Y, Lv C, Zhang X, et al. Protective effect of Qiliqiangxin against Doxorubicin-induced cardiomyopathy by suppressing excessive autophagy and apoptosis. Cardiovasc Ther. 2022;2022:9926635. https:\/\/doi.org\/10.1155\/2022\/9926635","journal-title":"Cardiovasc Ther"},{"key":"7673_CR138","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.yjmcc.2022.08.362","volume":"173","author":"J Nah","year":"2022","unstructured":"Nah J, Zablocki D, Sadoshima J. The role of autophagic cell death in cardiac disease. J Mol Cell Cardiol. 2022;173:16\u201324. https:\/\/doi.org\/10.1016\/j.yjmcc.2022.08.362","journal-title":"J Mol Cell Cardiol"},{"key":"7673_CR139","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.yjmcc.2014.03.007","volume":"71","author":"SE Wohlgemuth","year":"2014","unstructured":"Wohlgemuth SE, Calvani R, Marzetti E. The interplay between autophagy and mitochondrial dysfunction in oxidative stress-induced cardiac aging and pathology. J Mol Cell Cardiol. 2014;71:62\u201370. https:\/\/doi.org\/10.1016\/j.yjmcc.2014.03.007","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"7673_CR140","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10557-020-06941-x","volume":"34","author":"KN Timm","year":"2020","unstructured":"Timm KN, Tyler DJ. The role of AMPK activation for cardioprotection in doxorubicin-induced cardiotoxicity. Cardiovasc Drugs Ther. 2020;34(2):255\u201369. https:\/\/doi.org\/10.1007\/s10557-020-06941-x","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"7673_CR141","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00210-019-01624-3","volume":"392","author":"NT El-Said","year":"2019","unstructured":"El-Said NT, Mohamed EA, Taha RA. Irbesartan suppresses cardiac toxicity induced by doxorubicin via regulating the p38-MAPK\/NF-\u03baB and TGF-\u03b21 pathways. Naunyn Schmiedebergs Arch Pharmacol. 2019;392(6):647\u201358. https:\/\/doi.org\/10.1007\/s00210-019-01624-3","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"8","key":"7673_CR142","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.biopha.2014.09.010","volume":"68","author":"PA Janeesh","year":"2014","unstructured":"Janeesh PA, Abraham A. Robinin modulates doxorubicin-induced cardiac apoptosis by TGF-\u03b21 signaling pathway in Sprague Dawley rats. Biomed Pharmacother. 2014;68(8):989\u201398. https:\/\/doi.org\/10.1016\/j.biopha.2014.09.010","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"7673_CR143","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12272-017-0980-4","volume":"41","author":"L Chen","year":"2018","unstructured":"Chen L, Yan K-P, Liu X-C, et al. Valsartan regulates TGF-\u03b2\/Smads and TGF-\u03b2\/p38 pathways through lncRNA CHRF to improve doxorubicin-induced heart failure. Arch Pharm Res. 2018;41(1):101\u20139. https:\/\/doi.org\/10.1007\/s12272-017-0980-4","journal-title":"Arch Pharm Res"},{"key":"7673_CR144","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/DDDT.S269029","volume":"15","author":"S Zhang","year":"2021","unstructured":"Zhang S, Wu P, Liu J, Du Y, Yang Z. Roflumilast attenuates doxorubicin-induced cardiotoxicity by targeting inflammation and cellular senescence in cardiomyocytes mediated by SIRT1. Drug Des Devel Ther. 2021;15:87\u201397. https:\/\/doi.org\/10.2147\/DDDT.S269029","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"7673_CR145","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3892\/ijmm.2019.4393","volume":"45","author":"PP Huang","year":"2020","unstructured":"Huang PP, Fu J, Liu LH, et al. Honokiol antagonizes doxorubicin-induced cardiomyocyte senescence by inhibiting TXNIP-mediated NLRP3 inflammasome activation. Int J Mol Med. 2020;45(1):186\u201394. https:\/\/doi.org\/10.3892\/ijmm.2019.4393","journal-title":"Int J Mol Med"},{"issue":"1","key":"7673_CR146","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3892\/ijmm.2018.3635","volume":"42","author":"L Chen","year":"2018","unstructured":"Chen L, Xia W, Hou M. Mesenchymal stem cells attenuate doxorubicin-induced cellular senescence through the VEGF\/Notch\/TGF-\u03b2 signaling pathway in H9c2 cardiomyocytes. Int J Mol Med. 2018;42(1):674\u201384. https:\/\/doi.org\/10.3892\/ijmm.2018.3635","journal-title":"Int J Mol Med"},{"issue":"3","key":"7673_CR147","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jaccao.2023.03.012","volume":"5","author":"AN Linders","year":"2023","unstructured":"Linders AN, Dias IB, Ovchinnikova ES, et al. Evaluation of senescence and its prevention in doxorubicin-induced cardiotoxicity using dynamic engineered heart tissues. JACC CardioOncol. 2023;5(3):298\u2013315. https:\/\/doi.org\/10.1016\/j.jaccao.2023.03.012","journal-title":"JACC CardioOncol"},{"issue":"46","key":"7673_CR148","doi-asserted-by":"publisher","first-page":"65802","DOI":"10.1007\/s11356-021-15409-w","volume":"28","author":"SA Abdulkareem Aljumaily","year":"2021","unstructured":"Abdulkareem Aljumaily SA, Demir M, Elbe H, et al. Antioxidant, anti-inflammatory, and anti-apoptotic effects of crocin against doxorubicin-induced myocardial toxicity in rats. Environ Sci Pollut Res Int. 2021;28(46):65802\u201313. https:\/\/doi.org\/10.1007\/s11356-021-15409-w.","journal-title":"Environ Sci Pollut Res Int"},{"key":"7673_CR149","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/606183","volume":"2012","author":"J Dudka","year":"2012","unstructured":"Dudka J, Gieroba R, Korga A, et al. Different effects of resveratrol on dose-related doxorubicin-induced heart and liver toxicity. Evid Based Complement Alternat Med. 2012;2012:606183. https:\/\/doi.org\/10.1155\/2012\/606183.","journal-title":"Evid Based Complement Alternat Med"},{"key":"7673_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105882","volume":"173","author":"T Khuanjing","year":"2021","unstructured":"Khuanjing T, Ongnok B, Maneechote C, et al. Acetylcholinesterase inhibitor ameliorates doxorubicin-induced cardiotoxicity through reducing RIP1-mediated necroptosis. Pharmacol Res. 2021;173: 105882. https:\/\/doi.org\/10.1016\/j.phrs.2021.105882","journal-title":"Pharmacol Res"},{"issue":"1","key":"7673_CR151","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bbrc.2019.12.027","volume":"523","author":"X Yu","year":"2020","unstructured":"Yu X, Ruan Y, Huang X, et al. Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes. Biochem Biophys Res Commun. 2020;523(1):140\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2019.12.027","journal-title":"Biochem Biophys Res Commun"},{"key":"7673_CR152","doi-asserted-by":"publisher","unstructured":"Shipra, Tembhre MK, Hote MP, et al. PGC-1\u03b1 agonist rescues doxorubicin-induced cardiomyopathy by mitigating the oxidative stress and necroptosis. Antioxidants. 2023;12(9):1720. https:\/\/doi.org\/10.3390\/antiox12091720","DOI":"10.3390\/antiox12091720"},{"issue":"1","key":"7673_CR153","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10565-021-09649-2","volume":"39","author":"S Wu","year":"2023","unstructured":"Wu S, Lan J, Li L, et al. Sirt6 protects cardiomyocytes against doxorubicin-induced cardiotoxicity by inhibiting P53\/Fas-dependent cell death and augmenting endogenous antioxidant defense mechanisms. Cell Biol Toxicol. 2023;39(1):237\u201358. https:\/\/doi.org\/10.1007\/s10565-021-09649-2","journal-title":"Cell Biol Toxicol"},{"key":"7673_CR154","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.yjmcc.2017.10.008","volume":"114","author":"Y-P Yuan","year":"2018","unstructured":"Yuan Y-P, Ma Z-G, Zhang X, et al. CTRP3 protected against doxorubicin-induced cardiac dysfunction, inflammation and cell death via activation of Sirt1. J Mol Cell Cardiol. 2018;114:38\u201347. https:\/\/doi.org\/10.1016\/j.yjmcc.2017.10.008","journal-title":"J Mol Cell Cardiol"},{"key":"7673_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116412","volume":"463","author":"X-J Zhang","year":"2023","unstructured":"Zhang X-J, Li L, Wang A-L, et al. GSK2795039 prevents RIP1-RIP3-MLKL-mediated cardiomyocyte necroptosis in doxorubicin-induced heart failure through inhibition of NADPH oxidase-derived oxidative stress. Toxicol Appl Pharmacol. 2023;463: 116412. https:\/\/doi.org\/10.1016\/j.taap.2023.116412","journal-title":"Toxicol Appl Pharmacol"},{"key":"7673_CR156","doi-asserted-by":"publisher","first-page":"096032712110660","DOI":"10.1177\/09603271211066066","volume":"41","author":"Z Erdogmus Ozgen","year":"2022","unstructured":"Erdogmus Ozgen Z, Erdinc M, Kelle \u0130, Erdinc L, Nergiz Y. Protective effects of necrostatin-1 on doxorubicin-induced cardiotoxicity in rat heart. Hum Exp Toxicol. 2022;41:09603271211066066. https:\/\/doi.org\/10.1177\/09603271211066066","journal-title":"Hum Exp Toxicol"},{"issue":"1","key":"7673_CR157","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jphs.2024.06.005","volume":"156","author":"M Shimizu","year":"2024","unstructured":"Shimizu M, Ohwada W, Yano T, et al. Contribution of MLKL to the development of doxorubicin-induced cardiomyopathy and its amelioration by rapamycin. J Pharmacol Sci. 2024;156(1):9\u201318. https:\/\/doi.org\/10.1016\/j.jphs.2024.06.005","journal-title":"J Pharmacol Sci"},{"key":"7673_CR158","doi-asserted-by":"publisher","unstructured":"Shimizu M, Ohwada W, Yano, T et al. Rapamycin ameliorates doxorubicin-induced cardiomyopathy through suppression of RIPK1-independent necroptosis. Eur Heart J. 2023;44(Supplement_2):ehad655. https:\/\/doi.org\/10.1093\/eurheartj\/ehad655.3126.","DOI":"10.1093\/eurheartj\/ehad655.3126"},{"key":"7673_CR159","doi-asserted-by":"publisher","unstructured":"Chen X, Tian C, Zhang Z, et al. Astragaloside IV inhibits NLRP3 inflammasome-mediated pyroptosis via activation of Nrf-2\/HO-1 signaling pathway and protects against doxorubicin-induced cardiac dysfunction. Front Biosci. 2023;28(3):45. https:\/\/doi.org\/10.31083\/j.fbl2803045","DOI":"10.31083\/j.fbl2803045"},{"key":"7673_CR160","doi-asserted-by":"publisher","first-page":"1733834","DOI":"10.1155\/2022\/1733834","volume":"2022","author":"L Zhang","year":"2022","unstructured":"Zhang L, Fan C, Jiao H, et al. Calycosin Alleviates doxorubicin-induced cardiotoxicity and pyroptosis by inhibiting NLRP3 inflammasome activation. Oxid Med Cell Longev. 2022;2022:1733834. https:\/\/doi.org\/10.1155\/2022\/1733834","journal-title":"Oxid Med Cell Longev"},{"key":"7673_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112133","volume":"143","author":"L Zhang","year":"2021","unstructured":"Zhang L, Jiang Y-H, Fan C, et al. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis. Biomed Pharmacother. 2021;143: 112133. https:\/\/doi.org\/10.1016\/j.biopha.2021.112133","journal-title":"Biomed Pharmacother"},{"key":"7673_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2023.121334","volume":"321","author":"E Zhang","year":"2023","unstructured":"Zhang E, Shang C, Ma M, et al. Polyguluronic acid alleviates doxorubicin-induced cardiotoxicity by suppressing Peli1-NLRP3 inflammasome-mediated pyroptosis. Carbohydr Polym. 2023;321: 121334. https:\/\/doi.org\/10.1016\/j.carbpol.2023.121334","journal-title":"Carbohydr Polym"},{"key":"7673_CR163","doi-asserted-by":"publisher","unstructured":"Yu W, Qin X, Zhang Y, et al. Curcumin suppresses doxorubicin-induced cardiomyocyte pyroptosis via a PI3K\/Akt\/mTOR-dependent manner. Cardiovasc Diagn Ther. 2020;10(4):752\u201369. https:\/\/doi.org\/10.21037\/cdt-19-707","DOI":"10.21037\/cdt-19-707"},{"issue":"10","key":"7673_CR164","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3390\/cells8101224","volume":"8","author":"DK Singla","year":"2019","unstructured":"Singla DK, Johnson TA, Tavakoli DZ. Exosome treatment enhances anti-inflammatory M2 macrophages and reduces inflammation-induced pyroptosis in doxorubicin-induced cardiomyopathy. Cells. 2019;8(10):1224. https:\/\/doi.org\/10.3390\/cells8101224","journal-title":"Cells"},{"issue":"2","key":"7673_CR165","doi-asserted-by":"publisher","first-page":"H460","DOI":"10.1152\/ajpheart.00056.2019","volume":"317","author":"Z Tavakoli Dargani","year":"2019","unstructured":"Tavakoli Dargani Z, Singla DK. Embryonic stem cell-derived exosomes inhibit doxorubicin-induced TLR4-NLRP3-mediated cell death-pyroptosis. Am J Physiol Heart Circ Physiol. 2019;317(2):H460\u201371. https:\/\/doi.org\/10.1152\/ajpheart.00056.2019","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"7673_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114591","volume":"162","author":"W Zhang","year":"2023","unstructured":"Zhang W, Wang X, Tang Y, Huang C. Melatonin alleviates doxorubicin-induced cardiotoxicity via inhibiting oxidative stress, pyroptosis and apoptosis by activating Sirt1\/Nrf2 pathway. Biomed Pharmacother. 2023;162:114591. https:\/\/doi.org\/10.1016\/j.biopha.2023.114591","journal-title":"Biomed Pharmacother"},{"key":"7673_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.155105","volume":"121","author":"S Dai","year":"2023","unstructured":"Dai S, Chen Y, Fan X, et al. Emodin attenuates cardiomyocyte pyroptosis in doxorubicin-induced cardiotoxicity by directly binding to GSDMD. Phytomedicine. 2023;121:155105. https:\/\/doi.org\/10.1016\/j.phymed.2023.155105","journal-title":"Phytomedicine"},{"key":"7673_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102825","volume":"65","author":"B Wang","year":"2023","unstructured":"Wang B, Jin Y, Liu J, et al. EP1 activation inhibits doxorubicin-cardiomyocyte ferroptosis via Nrf2. Redox Biol. 2023;65: 102825. https:\/\/doi.org\/10.1016\/j.redox.2023.102825","journal-title":"Redox Biol"},{"issue":"9","key":"7673_CR169","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41419-020-02948-2","volume":"11","author":"Y Liu","year":"2020","unstructured":"Liu Y, Zeng L, Yang Y, et al. Acyl-CoA thioesterase 1 prevents cardiomyocytes from Doxorubicin-induced ferroptosis via shaping the lipid composition. Cell Death Dis. 2020;11(9):756. https:\/\/doi.org\/10.1038\/s41419-020-02948-2","journal-title":"Cell Death Dis"},{"key":"7673_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.133792","volume":"276","author":"Y Wang","year":"2024","unstructured":"Wang Y, Han J, Zhan S, et al. Fucoidan alleviates doxorubicin-induced cardiotoxicity by inhibiting ferroptosis via Nrf2\/GPX4 pathway. Int J Biol Macromol. 2024;276:133792. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.133792","journal-title":"Int J Biol Macromol"},{"issue":"10","key":"7673_CR171","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292124","volume":"18","author":"M Mao","year":"2023","unstructured":"Mao M, Zheng W, Deng B, et al. Cinnamaldehyde alleviates doxorubicin-induced cardiotoxicity by decreasing oxidative stress and ferroptosis in cardiomyocytes. PLoS ONE. 2023;18(10): e0292124. https:\/\/doi.org\/10.1371\/journal.pone.0292124","journal-title":"PLoS ONE"},{"issue":"10","key":"7673_CR172","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s41418-022-00990-5","volume":"29","author":"Y Wang","year":"2022","unstructured":"Wang Y, Yan S, Liu X, et al. PRMT4 promotes ferroptosis to aggravate doxorubicin-induced cardiomyopathy via inhibition of the Nrf2\/GPX4 pathway. Cell Death Differ. 2022;29(10):1982\u201395. https:\/\/doi.org\/10.1038\/s41418-022-00990-5","journal-title":"Cell Death Differ"},{"key":"7673_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103066","volume":"70","author":"H Zhang","year":"2024","unstructured":"Zhang H, Pan J, Huang S, et al. Hydrogen sulfide protects cardiomyocytes from doxorubicin-induced ferroptosis through the SLC7A11\/GSH\/GPx4 pathway by Keap1 S-sulfhydration and Nrf2 activation. Redox Biol. 2024;70: 103066. https:\/\/doi.org\/10.1016\/j.redox.2024.103066","journal-title":"Redox Biol"},{"issue":"08","key":"7673_CR174","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1142\/S0192415X22500902","volume":"50","author":"W Yu","year":"2022","unstructured":"Yu W, Chen C, Xu C, et al. Activation of p62-NRF2 axis protects against doxorubicin-induced ferroptosis in cardiomyocytes: a novel role and molecular mechanism of resveratrol. Am J Chin Med. 2022;50(08):2103\u201323. https:\/\/doi.org\/10.1142\/S0192415X22500902.","journal-title":"Am J Chin Med"},{"key":"7673_CR175","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.yjmcc.2021.08.006","volume":"161","author":"H Kitakata","year":"2021","unstructured":"Kitakata H, Endo J, Matsushima H, et al. MITOL\/MARCH5 determines the susceptibility of cardiomyocytes to doxorubicin-induced ferroptosis by regulating GSH homeostasis. J Mol Cell Cardiol. 2021;161:116\u201329. https:\/\/doi.org\/10.1016\/j.yjmcc.2021.08.006.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"7673_CR176","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1186\/s12967-023-04715-1","volume":"21","author":"P Tai","year":"2023","unstructured":"Tai P, Chen X, Jia G, et al. WGX50 mitigates doxorubicin-induced cardiotoxicity through inhibition of mitochondrial ROS and ferroptosis. J Transl Med. 2023;21(1):823. https:\/\/doi.org\/10.1186\/s12967-023-04715-1.","journal-title":"J Transl Med"},{"key":"7673_CR177","doi-asserted-by":"crossref","unstructured":"Tadokoro T, Ikeda M, Abe K, et al. Ethoxyquin is a Competent Radical-Trapping Antioxidant for Preventing Ferroptosis in Doxorubicin Cardiotoxicity. J Cardiovasc Pharmacol. 2022;80(5).","DOI":"10.1097\/FJC.0000000000001328"},{"key":"7673_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116794","volume":"482","author":"L Chen","year":"2024","unstructured":"Chen L, Sun X, Wang Z, et al. Resveratrol protects against doxorubicin-induced cardiotoxicity by attenuating ferroptosis through modulating the MAPK signaling pathway. Toxicol Appl Pharmacol. 2024;482:116794. https:\/\/doi.org\/10.1016\/j.taap.2023.116794","journal-title":"Toxicol Appl Pharmacol"},{"key":"7673_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114188","volume":"180","author":"J Zhang","year":"2020","unstructured":"Zhang J, Wang M, Ding W, et al. Resolvin E1 protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress, autophagy and apoptosis by targeting AKT\/mTOR signaling. Biochem Pharmacol. 2020;180: 114188. https:\/\/doi.org\/10.1016\/j.bcp.2020.114188","journal-title":"Biochem Pharmacol"},{"key":"7673_CR180","doi-asserted-by":"publisher","unstructured":"Gu J, Hu W, Song Z-p, et al. Resveratrol-induced autophagy promotes survival and attenuates doxorubicin-induced cardiotoxicity. Int Immunopharmacol. 2016:32:1\u20137. https:\/\/doi.org\/10.1016\/j.intimp.2016.01.002","DOI":"10.1016\/j.intimp.2016.01.002"},{"key":"7673_CR181","doi-asserted-by":"publisher","unstructured":"Cao Y, Shen T, Huang X, et al. Astragalus polysaccharide restores autophagic flux and improves cardiomyocyte function in doxorubicin-induced cardiotoxicity. Oncotarget. 2017;8(3):4837. https:\/\/doi.org\/10.18632\/oncotarget.13596","DOI":"10.18632\/oncotarget.13596"},{"issue":"10","key":"7673_CR182","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3390\/molecules22101589","volume":"22","author":"R Johnson","year":"2017","unstructured":"Johnson R, Shabalala S, Louw J, Kappo AP, Muller CJF. Aspalathin reverts doxorubicin-induced cardiotoxicity through increased autophagy and decreased expression of p53\/mTOR\/p62 signaling. Molecules. 2017;22(10):1589. https:\/\/doi.org\/10.3390\/molecules22101589","journal-title":"Molecules"},{"key":"7673_CR183","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fcvm.2020.00056","volume":"7","author":"H Kumari","year":"2020","unstructured":"Kumari H, Huang W-H, Chan MW. Review on the role of epigenetic modifications in doxorubicin-induced cardiotoxicity. Front Cardiovasc Med. 2020;7:56. https:\/\/doi.org\/10.3389\/fcvm.2020.00056","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"7673_CR184","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cts.12857","volume":"14","author":"M Tantawy","year":"2021","unstructured":"Tantawy M, Pamittan FG, Singh S, Gong Y. Epigenetic changes associated with anthracycline-induced cardiotoxicity. Clin Transl Sci. 2021;14(1):36\u201346. https:\/\/doi.org\/10.1111\/cts.12857","journal-title":"Clin Transl Sci"},{"issue":"1","key":"7673_CR185","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.mito.2009.09.006","volume":"10","author":"DC Wallace","year":"2010","unstructured":"Wallace DC, Fan W. Energetics, epigenetics, mitochondrial genetics. Mitochondrion. 2010;10(1):12\u201331. https:\/\/doi.org\/10.1016\/j.mito.2009.09.006","journal-title":"Mitochondrion"},{"key":"7673_CR186","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.tox.2017.08.011","volume":"390","author":"A Ferreira","year":"2017","unstructured":"Ferreira A, Cunha-Oliveira T, Sim\u00f5es RF, et al. Altered mitochondrial epigenetics associated with subchronic doxorubicin cardiotoxicity. Toxicology. 2017;390:63\u201373. https:\/\/doi.org\/10.1016\/j.tox.2017.08.011","journal-title":"Toxicology"},{"key":"7673_CR187","doi-asserted-by":"publisher","unstructured":"Liu D, Ma Z, Xu L, et al. PGC1\u03b1 activation by pterostilbene ameliorates acute doxorubicin cardiotoxicity by reducing oxidative stress via enhancing AMPK and SIRT1 cascades. Aging. 2019;11(22):10061. https:\/\/doi.org\/10.18632\/aging.102418","DOI":"10.18632\/aging.102418"},{"key":"7673_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2019.108834","volume":"313","author":"A Hanf","year":"2019","unstructured":"Hanf A, Oelze M, Manea A, et al. The anti-cancer drug doxorubicin induces substantial epigenetic changes in cultured cardiomyocytes. Chem Biol Interact. 2019;313: 108834. https:\/\/doi.org\/10.1016\/j.cbi.2019.108834","journal-title":"Chem Biol Interact"},{"key":"7673_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119107","volume":"284","author":"L Yang","year":"2021","unstructured":"Yang L, Yu Y, Tian G, Deng H, Yu B. H3K9ac modification was involved in doxorubicin induced apoptosis by regulating Pik3ca transcription in H9C2 cells. Life Sci. 2021;284: 119107. https:\/\/doi.org\/10.1016\/j.lfs.2021.119107","journal-title":"Life Sci"},{"key":"7673_CR190","doi-asserted-by":"publisher","unstructured":"Robinson EL, Ameri P, Delrue L, et al. Differential expression of epigenetic modifiers in early and late cardiotoxic heart failure reveals DNA methylation as a key regulator of cardiotoxicity. Front Cardiovasc Med. 2023;10. https:\/\/doi.org\/10.3389\/fcvm.2023.884174","DOI":"10.3389\/fcvm.2023.884174"},{"key":"7673_CR191","doi-asserted-by":"publisher","unstructured":"Zhu J-N, Fu Y-H, Hu Z-q, et al. Activation of miR-34a-5p\/Sirt1\/p66shc pathway contributes to doxorubicin-induced cardiotoxicity. Sci Rep. 2017;7(1):11879. https:\/\/doi.org\/10.1038\/s41598-017-12192-y","DOI":"10.1038\/s41598-017-12192-y"},{"key":"7673_CR192","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/597032","volume":"2015","author":"H Tony","year":"2015","unstructured":"Tony H, Yu K, Qiutang Z. MicroRNA-208a silencing attenuates doxorubicin induced myocyte apoptosis and cardiac dysfunction. Oxid Med Cell Longev. 2015;2015:597032. https:\/\/doi.org\/10.1155\/2015\/597032","journal-title":"Oxid Med Cell Longev"},{"issue":"9","key":"7673_CR193","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41419-019-1901-x","volume":"10","author":"J-A Pan","year":"2019","unstructured":"Pan J-A, Tang Y, Yu J-Y, et al. miR-146a attenuates apoptosis and modulates autophagy by targeting TAF9b\/P53 pathway in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2019;10(9):668. https:\/\/doi.org\/10.1038\/s41419-019-1901-x","journal-title":"Cell Death Dis"},{"key":"7673_CR194","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.884174","volume":"10","author":"EL Robinson","year":"2023","unstructured":"Robinson EL, Ameri P, Delrue L, et al. Differential expression of epigenetic modifiers in early and late cardiotoxic heart failure reveals DNA methylation as a key regulator of cardiotoxicity. Front Cardiovasc Med. 2023;10: 884174. https:\/\/doi.org\/10.3389\/fcvm.2023.884174","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"7673_CR195","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1042\/BST20221010","volume":"51","author":"G Zanini","year":"2023","unstructured":"Zanini G, Selleri V, Lopez Domenech S, et al. Mitochondrial DNA as inflammatory DAMP: a warning of an aging immune system? Biochem Soc Trans. 2023;51(2):735\u201345. https:\/\/doi.org\/10.1042\/BST20221010","journal-title":"Biochem Soc Trans"},{"issue":"Pt A","key":"7673_CR196","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.arr.2015.03.003","volume":"24","author":"J-W Kang","year":"2015","unstructured":"Kang J-W, Kim S-J, Cho H-I, Lee S-M. DAMPs activating innate immune responses in sepsis. Ageing Res Rev. 2015;24(Pt A):54\u201365. https:\/\/doi.org\/10.1016\/j.arr.2015.03.003","journal-title":"Ageing research reviews Ageing Res Rev"},{"issue":"4","key":"7673_CR197","doi-asserted-by":"publisher","DOI":"10.4110\/in.2018.18.e27","volume":"18","author":"JS Roh","year":"2018","unstructured":"Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory diseases. Immune Netw. 2018;18(4):e27. https:\/\/doi.org\/10.4110\/in.2018.18.e27","journal-title":"Immune Netw"},{"issue":"10","key":"7673_CR198","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.it.2007.08.004","volume":"28","author":"A Rubartelli","year":"2007","unstructured":"Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 2007;28(10):429\u201336. https:\/\/doi.org\/10.1016\/j.it.2007.08.004","journal-title":"Trends Immunol"},{"key":"7673_CR199","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.molmet.2017.11.002","volume":"7","author":"V Serbulea","year":"2018","unstructured":"Serbulea V, Upchurch CM, Ahern KW, et al. Macrophages sensing oxidized DAMPs reprogram their metabolism to support redox homeostasis and inflammation through a TLR2-Syk-ceramide dependent mechanism. Mol Metab. 2018;7:23\u201334. https:\/\/doi.org\/10.1016\/j.molmet.2017.11.002","journal-title":"Mol Metab"},{"issue":"7","key":"7673_CR200","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040763","volume":"7","author":"Y Ma","year":"2012","unstructured":"Ma Y, Zhang X, Bao H, et al. Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice. PLoS ONE. 2012;7(7):e40763. https:\/\/doi.org\/10.1371\/journal.pone.0040763","journal-title":"PLoS ONE"},{"issue":"24","key":"7673_CR201","doi-asserted-by":"publisher","first-page":"11013","DOI":"10.7150\/thno.47516","volume":"10","author":"ZG Ma","year":"2020","unstructured":"Ma ZG, Kong CY, Wu HM, et al. Toll-like receptor 5 deficiency diminishes doxorubicin-induced acute cardiotoxicity in mice. Theranostics. 2020;10(24):11013\u201325. https:\/\/doi.org\/10.7150\/thno.47516","journal-title":"Theranostics"},{"key":"7673_CR202","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2024.110140","volume":"761","author":"L Song","year":"2024","unstructured":"Song L, Qiu Q, Ju F, Zheng C. Mechanisms of doxorubicin-induced cardiac inflammation and fibrosis; therapeutic targets and approaches. Arch Biochem Biophys. 2024;761: 110140. https:\/\/doi.org\/10.1016\/j.abb.2024.110140","journal-title":"Arch Biochem Biophys"},{"key":"7673_CR203","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.947604","volume":"12","author":"A Bhagat","year":"2022","unstructured":"Bhagat A, Shrestha P, Jeyabal P, et al. Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase. Front Oncol. 2022;12:947604. https:\/\/doi.org\/10.3389\/fonc.2022.947604","journal-title":"Front Oncol"},{"issue":"1","key":"7673_CR204","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s00018-024-05169-4","volume":"81","author":"P Zhao","year":"2024","unstructured":"Zhao P, Li Y, Xu X, et al. Neutrophil extracellular traps mediate cardiomyocyte ferroptosis via the Hippo-Yap pathway to exacerbate doxorubicin-induced cardiotoxicity. Cell Mol Life Sci. 2024;81(1):122. https:\/\/doi.org\/10.1007\/s00018-024-05169-4","journal-title":"Cell Mol Life Sci"},{"key":"7673_CR205","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114576","volume":"162","author":"E Podyacheva","year":"2023","unstructured":"Podyacheva E, Danilchuk M, Toropova Y. Molecular mechanisms of endothelial remodeling under doxorubicin treatment. Biomed Pharmacother. 2023;162:114576. https:\/\/doi.org\/10.1016\/j.biopha.2023.114576","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"7673_CR206","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.200161","volume":"10","author":"T Dehghani","year":"2020","unstructured":"Dehghani T, Panitch A. Endothelial cells, neutrophils and platelets: getting to the bottom of an inflammatory triangle. Open Biol. 2020;10(10):200161. https:\/\/doi.org\/10.1098\/rsob.200161.","journal-title":"Open Biol"},{"issue":"8","key":"7673_CR207","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.biopha.2010.02.002","volume":"64","author":"R Santos","year":"2010","unstructured":"Santos R, Caperuto E, de Mello M, Rosa LC. Effect of doxorubicin on cytokine production by lymphocytes and the Th1\/Th2 balance. Biomed Pharmacother. 2010;64(8):579\u201381. https:\/\/doi.org\/10.1016\/j.biopha.2010.02.002","journal-title":"Biomed Pharmacother"},{"key":"7673_CR208","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.3389\/fimmu.2018.03029","volume":"9","author":"M Kurdi","year":"2018","unstructured":"Kurdi M, Zgheib C, Booz GW. Recent developments on the crosstalk between STAT3 and inflammation in heart function and disease. Front Immunol. 2018;9:3029. https:\/\/doi.org\/10.3389\/fimmu.2018.03029","journal-title":"Front Immunol"},{"issue":"1","key":"7673_CR209","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2174\/15701611113119990124","volume":"13","author":"W-S Lian","year":"2015","unstructured":"Lian W-S, Chiou H-C, Lin H, Chen J-J, Cheng C-F. The prostaglandin agonist beraprost aggravates doxorubicin-mediated apoptosis by increasing iNOS expression in cardiomyocytes. Curr Vasc Pharmacol. 2015;13(1):54\u201363. https:\/\/doi.org\/10.2174\/15701611113119990124","journal-title":"Curr Vasc Pharmacol"},{"issue":"12","key":"7673_CR210","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3390\/antiox10121897","volume":"10","author":"AK Bagchi","year":"2021","unstructured":"Bagchi AK, Malik A, Akolkar G, Jassal DS, Singal PK. Endoplasmic reticulum stress promotes iNOS\/NO and influences inflammation in the development of doxorubicin-induced cardiomyopathy. Antioxidants. 2021;10(12):1897. https:\/\/doi.org\/10.3390\/antiox10121897","journal-title":"Antioxidants"},{"issue":"5","key":"7673_CR211","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1042\/cs20130787","volume":"127","author":"N Parajuli","year":"2014","unstructured":"Parajuli N, Patel VB, Wang W, Basu R, Oudit GY. Loss of NOX2 (gp91phox) prevents oxidative stress and progression to advanced heart failure. Clin Sci. 2014;127(5):331\u201340. https:\/\/doi.org\/10.1042\/cs20130787","journal-title":"Clin Sci"},{"issue":"17","key":"7673_CR212","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1089\/ars.2013.5607","volume":"20","author":"A Konior","year":"2014","unstructured":"Konior A, Schramm A, Czesnikiewicz-Guzik M, Guzik TJ. NADPH oxidases in vascular pathology. Antioxid Redox Signal. 2014;20(17):2794\u2013814. https:\/\/doi.org\/10.1089\/ars.2013.5607","journal-title":"Antioxid Redox Signal"},{"key":"7673_CR213","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mad.2016.05.004","volume":"159","author":"E De Falco","year":"2016","unstructured":"De Falco E, Carnevale R, Pagano F, et al. Role of NOX2 in mediating doxorubicin-induced senescence in human endothelial progenitor cells. Mech Ageing Dev. 2016;159:37\u201343. https:\/\/doi.org\/10.1016\/j.mad.2016.05.004","journal-title":"Mech Ageing Dev"},{"key":"7673_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116672","volume":"477","author":"H Zhao","year":"2023","unstructured":"Zhao H, Lin X, Chen Q, et al. Quercetin inhibits the NOX2\/ROS-mediated NF-\u03baB\/TXNIP signaling pathway to ameliorate pyroptosis of cardiomyocytes to relieve sepsis-induced cardiomyopathy. Toxicol Appl Pharmacol. 2023;477: 116672. https:\/\/doi.org\/10.1016\/j.taap.2023.116672","journal-title":"Toxicol Appl Pharmacol"},{"issue":"15","key":"7673_CR215","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1177\/1535370219868960","volume":"244","author":"MA Caporizzo","year":"2019","unstructured":"Caporizzo MA, Chen CY, Prosser BL. Cardiac microtubules in health and heart disease. Exp Biol Med. 2019;244(15):1255\u201372. https:\/\/doi.org\/10.1177\/1535370219868960","journal-title":"Exp Biol Med"},{"issue":"11","key":"7673_CR216","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1093\/cvr\/cvab019","volume":"117","author":"AS Mighiu","year":"2021","unstructured":"Mighiu AS, Recalde A, Ziberna K, et al. Inducibility, but not stability, of atrial fibrillation is increased by NOX2 overexpression in mice. Cardiovasc Res. 2021;117(11):2354\u201364. https:\/\/doi.org\/10.1093\/cvr\/cvab019","journal-title":"Cardiovasc Res"},{"issue":"17","key":"7673_CR217","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94248","volume":"2","author":"LC Joseph","year":"2017","unstructured":"Joseph LC, Kokkinaki D, Valenti M-C, et al. Inhibition of NADPH oxidase 2 (NOX2) prevents sepsis-induced cardiomyopathy by improving calcium handling and mitochondrial function. JCI Insight. 2017;2(17): e94248. https:\/\/doi.org\/10.1172\/jci.insight.94248","journal-title":"JCI Insight"},{"issue":"21","key":"7673_CR218","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1111\/bph.13773","volume":"174","author":"D McLaughlin","year":"2017","unstructured":"McLaughlin D, Zhao Y, O\u2019Neill KM, et al. Signalling mechanisms underlying doxorubicin and Nox2 NADPH oxidase-induced cardiomyopathy: involvement of mitofusin-2. Br J Pharmacol. 2017;174(21):3677\u201395. https:\/\/doi.org\/10.1111\/bph.13773","journal-title":"Br J Pharmacol"},{"key":"7673_CR219","doi-asserted-by":"publisher","unstructured":"Rocic P, Lucchesi PA. NAD (P) H Oxidases and TGF-\u03b2\u2013Induced Cardiac Fibroblast Differentiation: Nox-4 Gets Smad. Am Heart Assoc; 2005. 28;97(9):850\u20132. https:\/\/doi.org\/10.1161\/01.RES.0000190403.87462.bf","DOI":"10.1161\/01.RES.0000190403.87462.bf"},{"issue":"14","key":"7673_CR220","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1089\/ars.2014.6238","volume":"23","author":"C Hirschh\u00e4user","year":"2015","unstructured":"Hirschh\u00e4user C, Bornbaum J, Reis A, et al. NOX4 in mitochondria: yeast two-hybrid-based interaction with complex i without relevance for basal reactive oxygen species? Antioxid Redox Signal. 2015;23(14):1106\u201312. https:\/\/doi.org\/10.1089\/ars.2014.6238","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"7673_CR221","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41420-023-01528-5","volume":"9","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zou Z, G\u0103man M-A, Xu L, Li J. NADPH oxidase mediated oxidative stress signaling in FLT3-ITD acute myeloid leukemia. Cell death discovery. 2023;9(1):208. https:\/\/doi.org\/10.1038\/s41420-023-01528-5","journal-title":"Cell death discovery"},{"key":"7673_CR222","doi-asserted-by":"publisher","unstructured":"Aryafar T, Amini P, Rezapoor S, et al. Modulation of radiation-induced NADPH oxidases in rat\u2019s heart tissues by melatonin. J Biomed Phys Eng. 2021;11(4):465\u201372. https:\/\/doi.org\/10.31661\/jbpe.v0i0.1094","DOI":"10.31661\/jbpe.v0i0.1094"},{"key":"7673_CR223","doi-asserted-by":"publisher","unstructured":"Kolivand S, Amini P, Saffar H, et al. Selenium-L-methionine modulates radiation injury and Duox1 and Duox2 upregulation in rat\u2019s heart tissues. J Cardiovasc Thorac Res. 2019;11(2):121\u20136. https:\/\/doi.org\/10.15171\/jcvtr.2019.21","DOI":"10.15171\/jcvtr.2019.21"},{"key":"7673_CR224","doi-asserted-by":"publisher","unstructured":"Zeng H, Zou P, Chen Y, Zhang P, Shao L. NOX4 aggravates doxorubicin-induced cardiomyocyte pyroptosis by increasing reactive oxygen species content and activating the NLRP3 inflammasome. Cardiovasc Diagn Ther. 2024;14(1):84\u2013100. https:\/\/doi.org\/10.21037\/cdt-23-142","DOI":"10.21037\/cdt-23-142"},{"issue":"4","key":"7673_CR225","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41569-023-00946-3","volume":"21","author":"S Toldo","year":"2024","unstructured":"Toldo S, Abbate A. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. Nat Rev Cardiol. 2024;21(4):219\u201337. https:\/\/doi.org\/10.1038\/s41569-023-00946-3","journal-title":"Nat Rev Cardiol"},{"key":"7673_CR226","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.yjmcc.2022.07.005","volume":"171","author":"Y Gao","year":"2022","unstructured":"Gao Y, Shi H, Dong Z, et al. Current knowledge of pyroptosis in heart diseases. J Mol Cell Cardiol. 2022;171:81\u20139. https:\/\/doi.org\/10.1016\/j.yjmcc.2022.07.005","journal-title":"J Mol Cell Cardiol"},{"key":"7673_CR227","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2022.101207","volume":"89","author":"AM Astudillo","year":"2023","unstructured":"Astudillo AM, Balboa MA, Balsinde J. Compartmentalized regulation of lipid signaling in oxidative stress and inflammation: Plasmalogens, oxidized lipids and ferroptosis as new paradigms of bioactive lipid research. Prog Lipid Res. 2023;89: 101207. https:\/\/doi.org\/10.1016\/j.plipres.2022.101207","journal-title":"Prog Lipid Res"},{"issue":"1","key":"7673_CR228","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13578-023-01169-2","volume":"13","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Luo Y, Peng L, et al. Ferroptosis in cardiovascular diseases: role and mechanism. Cell Biosci. 2023;13(1):226. https:\/\/doi.org\/10.1186\/s13578-023-01169-2","journal-title":"Cell Biosci"},{"key":"7673_CR229","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115354","volume":"207","author":"Z Sun","year":"2023","unstructured":"Sun Z, Fang C, Xu S, et al. SIRT3 attenuates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome via autophagy. Biochem Pharmacol. 2023;207:115354. https:\/\/doi.org\/10.1016\/j.bcp.2022.115354","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"7673_CR230","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s12012-022-09762-6","volume":"22","author":"T Panpan","year":"2022","unstructured":"Panpan T, Yuchen D, Xianyong S, et al. Cardiac remodelling following cancer therapy: a review. Cardiovasc Toxicol. 2022;22(9):771\u201386. https:\/\/doi.org\/10.1007\/s12012-022-09762-6","journal-title":"Cardiovasc Toxicol"},{"issue":"1","key":"7673_CR231","doi-asserted-by":"publisher","first-page":"6971","DOI":"10.1038\/s41598-024-57090-2","volume":"14","author":"Y Ma","year":"2024","unstructured":"Ma Y, Zhao HP, Yang LG, et al. NADPH oxidase 2 mediates cardiac sympathetic denervation and myocyte autophagy, resulting in cardiac atrophy and dysfunction in doxorubicin-induced cardiomyopathy. Sci Rep. 2024;14(1):6971. https:\/\/doi.org\/10.1038\/s41598-024-57090-2","journal-title":"Sci Rep"},{"key":"7673_CR232","doi-asserted-by":"publisher","unstructured":"Shimauchi T, Numaga-Tomita T, Ito T, et al. TRPC3-Nox2 complex mediates doxorubicin-induced myocardial atrophy. JCI Insight. 2017;2(15). https:\/\/doi.org\/10.1172\/jci.insight.93358","DOI":"10.1172\/jci.insight.93358"},{"key":"7673_CR233","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176351","volume":"967","author":"HP Zhao","year":"2024","unstructured":"Zhao HP, Ma Y, Zhang XJ, et al. NADPH oxidase 2 inhibitor GSK2795039 prevents doxorubicin-induced cardiac atrophy by attenuating cardiac sympathetic nerve terminal abnormalities and myocyte autophagy. Eur J Pharmacol. 2024;967: 176351. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176351","journal-title":"Eur J Pharmacol"},{"key":"7673_CR234","doi-asserted-by":"publisher","unstructured":"Zhang H, Wang Z, Liu Z, Du K, Lu X. Protective Effects of Dexazoxane on Rat Ferroptosis in Doxorubicin-Induced Cardiomyopathy Through Regulating HMGB1. Front Cardiovasc Med. 2021;8. https:\/\/doi.org\/10.3389\/fcvm.2021.685434","DOI":"10.3389\/fcvm.2021.685434"},{"issue":"2","key":"7673_CR235","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00280-008-0744-4","volume":"63","author":"P Xiang","year":"2009","unstructured":"Xiang P, Deng HY, Li K, et al. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model. Cancer Chemother Pharmacol. 2009;63(2):343\u20139. https:\/\/doi.org\/10.1007\/s00280-008-0744-4","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"7673_CR236","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/CAD.0000000000000514","volume":"28","author":"E Tahover","year":"2017","unstructured":"Tahover E, Segal A, Isacson R, et al. Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival. Anticancer Drugs. 2017;28(7):787\u201394. https:\/\/doi.org\/10.1097\/CAD.0000000000000514","journal-title":"Anticancer Drugs"},{"key":"7673_CR237","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.biopha.2018.07.037","volume":"109","author":"Q-L Zhang","year":"2019","unstructured":"Zhang Q-L, Yang J-J, Zhang H-S. Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy. Biomed Pharmacother. 2019;109:71\u201383. https:\/\/doi.org\/10.1016\/j.biopha.2018.07.037","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"7673_CR238","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/antiox9020159","volume":"9","author":"AM Alanazi","year":"2020","unstructured":"Alanazi AM, Fadda L, Alhusaini A, et al. Liposomal resveratrol and\/or carvedilol attenuate doxorubicin-induced cardiotoxicity by modulating inflammation, oxidative stress and S100A1 in rats. Antioxidants. 2020;9(2):159. https:\/\/doi.org\/10.3390\/antiox9020159","journal-title":"Antioxidants"},{"key":"7673_CR239","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116794","volume":"482","author":"E Tatlidede","year":"2024","unstructured":"Tatlidede E, \u015eehirli \u00d6, Velio\u011flu-\u00d6\u011f\u00fcn\u00e7 A, et al. Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Toxicol Appl Pharmacol. 2024;482: 116794. https:\/\/doi.org\/10.1016\/j.taap.2023.116794","journal-title":"Toxicol Appl Pharmacol"},{"issue":"12","key":"7673_CR240","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/1873-3468.14091","volume":"595","author":"ZH Maayah","year":"2021","unstructured":"Maayah ZH, Alam AS, Takahara S, et al. Resveratrol reduces cardiac NLRP3-inflammasome activation and systemic inflammation to lessen doxorubicin-induced cardiotoxicity in juvenile mice. FEBS Lett. 2021;595(12):1681\u201395. https:\/\/doi.org\/10.1002\/1873-3468.14091","journal-title":"FEBS Lett"},{"issue":"2","key":"7673_CR241","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s12012-021-09710-w","volume":"22","author":"G Ibrahim Fouad","year":"2022","unstructured":"Ibrahim Fouad G, Ahmed KA. Curcumin ameliorates doxorubicin-induced cardiotoxicity and hepatotoxicity via suppressing oxidative stress and modulating iNOS, NF-\u03baB, and TNF-\u03b1 in rats. Cardiovasc Toxicol. 2022;22(2):152\u201366. https:\/\/doi.org\/10.1007\/s12012-021-09710-w","journal-title":"Cardiovasc Toxicol"},{"key":"7673_CR242","doi-asserted-by":"publisher","unstructured":"Benzer F, Kandemir FM, Ozkaraca M, Kucukler S, Caglayan C. Curcumin ameliorates doxorubicin-induced cardiotoxicity by abrogation of inflammation, apoptosis, oxidative DNA damage, and protein oxidation in rats. J Biochem Mol Toxicol. 2018;32(2). https:\/\/doi.org\/10.1002\/jbt.22030","DOI":"10.1002\/jbt.22030"},{"issue":"12","key":"7673_CR243","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.116.005797","volume":"9","author":"GC Mel\u00e9ndez","year":"2016","unstructured":"Mel\u00e9ndez GC, Hundley WG. Is myocardial fibrosis a new frontier for discovery in cardiotoxicity related to the administration of anthracyclines? Circ Cardiovasc Imaging. 2016;9(12): e005797. https:\/\/doi.org\/10.1161\/CIRCIMAGING.116.005797","journal-title":"Circ Cardiovasc Imaging"},{"key":"7673_CR244","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.yjmcc.2015.11.002","volume":"94","author":"NA Turner","year":"2016","unstructured":"Turner NA. Inflammatory and fibrotic responses of cardiac fibroblasts to myocardial damage associated molecular patterns (DAMPs). J Mol Cell Cardiol. 2016;94:189\u2013200. https:\/\/doi.org\/10.1016\/j.yjmcc.2015.11.002","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"7673_CR245","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/jcb.29840","volume":"122","author":"S Upadhyay","year":"2021","unstructured":"Upadhyay S, Gupta KB, Mantha AK, Dhiman M. A short review: doxorubicin and its effect on cardiac proteins. J Cell Biochem. 2021;122(2):153\u201365. https:\/\/doi.org\/10.1002\/jcb.29840","journal-title":"J Cell Biochem"},{"issue":"3","key":"7673_CR246","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.118.11065","volume":"72","author":"G Jia","year":"2018","unstructured":"Jia G, Aroor AR, Hill MA, Sowers JR. Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness. Hypertension. 2018;72(3):537\u201348. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11065","journal-title":"Hypertension"},{"issue":"1","key":"7673_CR247","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2174\/1874467211666181010154709","volume":"12","author":"K Mortezaee","year":"2019","unstructured":"Mortezaee K, Goradel NH, Amini P, et al. NADPH oxidase as a target for modulation of radiation response; implications to carcinogenesis and radiotherapy. Curr Mol Pharmacol. 2019;12(1):50\u201360. https:\/\/doi.org\/10.2174\/1874467211666181010154709","journal-title":"Curr Mol Pharmacol"},{"key":"7673_CR248","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.freeradbiomed.2018.03.053","volume":"120","author":"K Iwata","year":"2018","unstructured":"Iwata K, Matsuno K, Murata A, et al. Up-regulation of NOX1\/NADPH oxidase following drug-induced myocardial injury promotes cardiac dysfunction and fibrosis. Free Rad Biol Med. 2018;120:277\u201388. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.03.053","journal-title":"Free Rad Biol Med"},{"issue":"5","key":"7673_CR249","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.phrs.2009.05.007","volume":"60","author":"MA Ibrahim","year":"2009","unstructured":"Ibrahim MA, Ashour OM, Ibrahim YF, et al. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res. 2009;60(5):373\u201381. https:\/\/doi.org\/10.1016\/j.phrs.2009.05.007","journal-title":"Pharmacol Res"},{"issue":"11","key":"7673_CR250","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166525","volume":"1868","author":"JA Espitia-Corredor","year":"2022","unstructured":"Espitia-Corredor JA, Shamoon L, Olivares-Silva F, et al. Resolvin E1 attenuates doxorubicin-induced cardiac fibroblast senescence: a key role for IL-1\u03b2. Biochim Biophys Acta Mol Basis Dis. 2022;1868(11): 166525. https:\/\/doi.org\/10.1016\/j.bbadis.2022.166525","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"3","key":"7673_CR251","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s13105-014-0339-y","volume":"70","author":"MH Arafa","year":"2014","unstructured":"Arafa MH, Mohammad NS, Atteia HH, Abd-Elaziz HR. Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. J Physiol Biochem. 2014;70(3):701\u201311. https:\/\/doi.org\/10.1007\/s13105-014-0339-y","journal-title":"J Physiol Biochem"},{"issue":"7","key":"7673_CR252","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22492","volume":"34","author":"A Alanazi","year":"2020","unstructured":"Alanazi A, Fadda L, Alhusaini A, Ahmad R. Antioxidant, antiapoptotic, and antifibrotic effects of the combination of liposomal resveratrol and carvedilol against doxorubicin-induced cardiomyopathy in rats. J Biochem Mol Toxicol. 2020;34(7):e22492. https:\/\/doi.org\/10.1002\/jbt.22492","journal-title":"J Biochem Mol Toxicol"},{"issue":"11","key":"7673_CR253","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3390\/ph13110348","volume":"13","author":"MA Saleh","year":"2020","unstructured":"Saleh MA, Antar SA, Hazem RM, El-Azab MF. Pirfenidone and vitamin D ameliorate cardiac fibrosis induced by doxorubicin in Ehrlich ascites carcinoma bearing mice: modulation of monocyte chemoattractant protein-1 and Jun N-terminal kinase-1 pathways. Pharmaceuticals. 2020;13(11):348. https:\/\/doi.org\/10.3390\/ph13110348","journal-title":"Pharmaceuticals"},{"issue":"22","key":"7673_CR254","doi-asserted-by":"publisher","first-page":"9287","DOI":"10.1158\/0008-5472.CAN-10-2664","volume":"70","author":"Y Zhao","year":"2010","unstructured":"Zhao Y, McLaughlin D, Robinson E, et al. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy. Cancer Res. 2010;70(22):9287\u201397. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2664","journal-title":"Cancer Res"},{"key":"7673_CR255","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172490","volume":"859","author":"J Lin","year":"2019","unstructured":"Lin J, Fang L, Li H, et al. Astragaloside IV alleviates doxorubicin induced cardiomyopathy by inhibiting NADPH oxidase derived oxidative stress. Eur J Pharmacol. 2019;859:172490. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172490","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"7673_CR256","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.3892\/mmr.2020.11521","volume":"22","author":"D Cheng","year":"2020","unstructured":"Cheng D, Chen L, Tu W, et al. Protective effects of valsartan administration on doxorubicin-induced myocardial injury in rats and the role of oxidative stress and NOX2\/NOX4 signaling. Mol Med Rep. 2020;22(5):4151\u201362. https:\/\/doi.org\/10.3892\/mmr.2020.11521","journal-title":"Mol Med Rep"},{"key":"7673_CR257","doi-asserted-by":"publisher","first-page":"1118002","DOI":"10.3389\/fcvm.2023.1118002","volume":"10","author":"F Zhou","year":"2023","unstructured":"Zhou F, Zhu X, Liu Y, et al. Coronary atherosclerosis and chemotherapy: from bench to bedside. Front Cardiovasc Med. 2023;10:1118002. https:\/\/doi.org\/10.3389\/fcvm.2023.1118002","journal-title":"Front Cardiovasc Med"},{"key":"7673_CR258","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.toxlet.2021.04.015","volume":"346","author":"M Bosman","year":"2021","unstructured":"Bosman M, Favere K, Neutel CH, et al. Doxorubicin induces arterial stiffness: a comprehensive in vivo and ex vivo evaluation of vascular toxicity in mice. Toxicol Lett. 2021;346:23\u201333. https:\/\/doi.org\/10.1016\/j.toxlet.2021.04.015","journal-title":"Toxicol Lett"},{"key":"7673_CR259","doi-asserted-by":"publisher","unstructured":"Boutin G, Yuzugulen J, Pranjol MZI. Endothelin-based markers for endothelial dysfunction in chemotherapy-induced cardiotoxicity. J Mol Cell Cardiol Plus. 2023:100053. https:\/\/doi.org\/10.1016\/j.jmccpl.2023.100053","DOI":"10.1016\/j.jmccpl.2023.100053"},{"key":"7673_CR260","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.pharep.2015.03.022","volume":"67","author":"T Wojcik","year":"2015","unstructured":"Wojcik T, Szczesny E, Chlopicki S. Detrimental effects of chemotherapeutics and other drugs on the endothelium: a call for endothelial toxicity profiling. Pharmacol Rep. 2015;67:811\u20137. https:\/\/doi.org\/10.1016\/j.pharep.2015.03.022","journal-title":"Pharmacol Rep"},{"issue":"2","key":"7673_CR261","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057554","volume":"8","author":"DM Eckman","year":"2013","unstructured":"Eckman DM, Stacey RB, Rowe R, et al. Weekly doxorubicin increases coronary arteriolar wall and adventitial thickness. PLoS ONE. 2013;8(2):e57554. https:\/\/doi.org\/10.1371\/journal.pone.0057554","journal-title":"PLoS ONE"},{"issue":"23","key":"7673_CR262","doi-asserted-by":"publisher","first-page":"12812","DOI":"10.3390\/ijms222312812","volume":"22","author":"M Bosman","year":"2021","unstructured":"Bosman M, Kr\u00fcger DN, Favere K, et al. Doxorubicin impairs smooth muscle cell contraction: novel insights in vascular toxicity. Int J Mol Sci. 2021;22(23):12812. https:\/\/doi.org\/10.3390\/ijms222312812","journal-title":"Int J Mol Sci"},{"issue":"13","key":"7673_CR263","doi-asserted-by":"publisher","DOI":"10.1172\/JCI149117","volume":"132","author":"P Szczepaniak","year":"2022","unstructured":"Szczepaniak P, Siedlinski M, Hodorowicz-Zaniewska D, et al. Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism. J Clin Invest. 2022;132(13): e149117. https:\/\/doi.org\/10.1172\/JCI149117","journal-title":"J Clin Invest"},{"issue":"2","key":"7673_CR264","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s13105-012-0200-0","volume":"69","author":"R Hayward","year":"2013","unstructured":"Hayward R, Hydock D, Gibson N, et al. Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function. J Physiol Biochem. 2013;69(2):177\u201387. https:\/\/doi.org\/10.1007\/s13105-012-0200-0","journal-title":"J Physiol Biochem"},{"issue":"1","key":"7673_CR265","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40959-021-00100-3","volume":"7","author":"RK Hoffman","year":"2021","unstructured":"Hoffman RK, Kim B-J, Shah PD, et al. Damage to cardiac vasculature may be associated with breast cancer treatment-induced cardiotoxicity. Cardiooncology. 2021;7(1):15. https:\/\/doi.org\/10.1186\/s40959-021-00100-3","journal-title":"Cardiooncology"},{"key":"7673_CR266","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.3389\/fphar.2019.01531","volume":"10","author":"H He","year":"2020","unstructured":"He H, Wang L, Qiao Y, et al. Doxorubicin induces endotheliotoxicity and mitochondrial dysfunction via ROS\/eNOS\/NO pathway. Front Pharmacol. 2020;10:1531. https:\/\/doi.org\/10.3389\/fphar.2019.01531","journal-title":"Front Pharmacol"},{"key":"7673_CR267","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110525","volume":"130","author":"A Xu","year":"2020","unstructured":"Xu A, Deng F, Chen Y, et al. NF-\u03baB pathway activation during endothelial-to-mesenchymal transition in a rat model of doxorubicin-induced cardiotoxicity. Biomed Pharmacother. 2020;130:110525. https:\/\/doi.org\/10.1016\/j.biopha.2020.110525","journal-title":"Biomed Pharmacother"},{"key":"7673_CR268","doi-asserted-by":"publisher","unstructured":"Badescu MC, Badulescu OV, Scripcariu DV, et al. Myocardialischemia related to common cancer therapy-prevention insights. Life. 2022;12(7). https:\/\/doi.org\/10.3390\/life12071034","DOI":"10.3390\/life12071034"},{"issue":"2","key":"7673_CR269","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/cvr\/cvab053","volume":"118","author":"C Galan-Arriola","year":"2022","unstructured":"Galan-Arriola C, V\u00edlchez-Tschischke JP, Lobo M, et al. Coronary microcirculation damage in anthracycline cardiotoxicity. Cardiovasc Res. 2022;118(2):531\u201341. https:\/\/doi.org\/10.1093\/cvr\/cvab053","journal-title":"Cardiovasc Res"},{"issue":"1","key":"7673_CR270","doi-asserted-by":"publisher","first-page":"H133","DOI":"10.1152\/ajpheart.00456.2019","volume":"319","author":"H Lv","year":"2020","unstructured":"Lv H, Tan R, Liao J, et al. Doxorubicin contributes to thrombus formation and vascular injury by interfering with platelet function. Am J Physiol Heart Circ Physiol. 2020;319(1):H133\u201343. https:\/\/doi.org\/10.1152\/ajpheart.00456.2019","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"7673_CR271","doi-asserted-by":"publisher","first-page":"H2413","DOI":"10.1152\/ajpheart.01096.2010","volume":"301","author":"HI Ammar","year":"2011","unstructured":"Ammar HI, Saba S, Ammar RI, et al. Erythropoietin protects against doxorubicin-induced heart failure. Am J Physiol Heart Circ Physiol. 2011;301(6):H2413\u201321. https:\/\/doi.org\/10.1152\/ajpheart.01096.2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"7673_CR272","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.tox.2019.05.016","volume":"423","author":"X Li","year":"2019","unstructured":"Li X, Gu J, Zhang Y, et al. L-arginine alleviates doxorubicin-induced endothelium-dependent dysfunction by promoting nitric oxide generation and inhibiting apoptosis. Toxicology. 2019;423:105\u201311. https:\/\/doi.org\/10.1016\/j.tox.2019.05.016","journal-title":"Toxicology"},{"key":"7673_CR273","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102120","volume":"46","author":"JA Pan","year":"2021","unstructured":"Pan JA, Zhang H, Lin H, et al. Irisin ameliorates doxorubicin-induced cardiac perivascular fibrosis through inhibiting endothelial-to-mesenchymal transition by regulating ROS accumulation and autophagy disorder in endothelial cells. Redox Biol. 2021;46:102120. https:\/\/doi.org\/10.1016\/j.redox.2021.102120","journal-title":"Redox Biol"},{"issue":"3","key":"7673_CR274","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00109-016-1494-0","volume":"95","author":"C Kankeu","year":"2017","unstructured":"Kankeu C, Clarke K, Passante E, Huber HJ. Doxorubicin-induced chronic dilated cardiomyopathy\u2014the apoptosis hypothesis revisited. J Mol Med. 2017;95(3):239\u201348. https:\/\/doi.org\/10.1007\/s00109-016-1494-0","journal-title":"J Mol Med"},{"issue":"1","key":"7673_CR275","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ihj.2015.02.012","volume":"67","author":"SK Maulik","year":"2015","unstructured":"Maulik SK, Mishra S. Hypertrophy to failure: what goes wrong with the fibers of the heart? Indian Heart J. 2015;67(1):66\u20139. https:\/\/doi.org\/10.1016\/j.ihj.2015.02.012","journal-title":"Indian Heart J"},{"key":"7673_CR276","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fcvm.2019.00020","volume":"6","author":"R Gogiraju","year":"2019","unstructured":"Gogiraju R, Bochenek ML, Sch\u00e4fer K. Angiogenic endothelial cell signaling in cardiac hypertrophy and heart failure. Front Cardiovasc Med. 2019;6:20. https:\/\/doi.org\/10.3389\/fcvm.2019.00020","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"7673_CR277","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1124\/jpet.300.3.1101","volume":"300","author":"VC Tu","year":"2002","unstructured":"Tu VC, Bahl JJ, Chen QM. Signals of oxidant-induced cardiomyocyte hypertrophy: key activation of p70 S6 kinase-1 and phosphoinositide 3-kinase. J Pharmacol Exp Ther. 2002;300(3):1101\u201310. https:\/\/doi.org\/10.1124\/jpet.300.3.1101","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"7673_CR278","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2174\/187152908784533702","volume":"8","author":"SH Gutierrez","year":"2008","unstructured":"Gutierrez SH, Kuri MR, del Castillo ER. Cardiac role of the transcription factor NF-\u03baB. Cardiovasc Hematol Disord Drug Targets. 2008;8(2):153\u201360. https:\/\/doi.org\/10.2174\/187152908784533702","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"12","key":"7673_CR279","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029055","volume":"6","author":"A Leychenko","year":"2011","unstructured":"Leychenko A, Konorev E, Jijiwa M, Matter ML. Stretch-induced hypertrophy activates NFkB-mediated VEGF secretion in adult cardiomyocytes. PLoS ONE. 2011;6(12):e29055. https:\/\/doi.org\/10.1371\/journal.pone.0029055","journal-title":"PLoS ONE"},{"issue":"5","key":"7673_CR280","doi-asserted-by":"publisher","first-page":"H1685","DOI":"10.1152\/ajpheart.00266.2001","volume":"282","author":"B Wang","year":"2002","unstructured":"Wang B, Hao J, Jones SC, et al. Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am J Physiol Heart Circ Physiol. 2002;282(5):H1685\u201396. https:\/\/doi.org\/10.1152\/ajpheart.00266.2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"7673_CR281","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1080\/13813455.2020.1773864","volume":"128","author":"M Najafi","year":"2022","unstructured":"Najafi M, Tavakol S, Zarrabi A, Ashrafizadeh M. Dual role of quercetin in enhancing the efficacy of cisplatin in chemotherapy and protection against its side effects: a review. Arch Physiol Biochem. 2022;128(6):1438\u201352. https:\/\/doi.org\/10.1080\/13813455.2020.1773864","journal-title":"Arch Physiol Biochem"},{"key":"7673_CR282","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118984","volume":"267","author":"C Zhan","year":"2021","unstructured":"Zhan C, Bai N, Zheng M, et al. Tranilast prevents doxorubicin-induced myocardial hypertrophy and angiotensin II synthesis in rats. Life Sci. 2021;267:118984. https:\/\/doi.org\/10.1016\/j.lfs.2020.118984","journal-title":"Life Sci"},{"issue":"7","key":"7673_CR283","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.23054","volume":"36","author":"BP Lohanathan","year":"2022","unstructured":"Lohanathan BP, Rathinasamy B, Huang CY, Viswanadha VP. Neferine attenuates doxorubicin-induced fibrosis and hypertrophy in H9c2 cells. J Biochem Mol Toxicol. 2022;36(7):e23054. https:\/\/doi.org\/10.1002\/jbt.23054","journal-title":"J Biochem Mol Toxicol"},{"issue":"6","key":"7673_CR284","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.3390\/ijms22063269","volume":"22","author":"AM Alzahrani","year":"2021","unstructured":"Alzahrani AM, Rajendran P, Veeraraghavan VP, Hanieh H. Cardiac protective effect of kirenol against doxorubicin-induced cardiac hypertrophy in H9c2 cells through Nrf2 signaling via PI3K\/AKT pathways. Int J Mol Sci. 2021;22(6):3269. https:\/\/doi.org\/10.3390\/ijms22063269","journal-title":"Int J Mol Sci"},{"issue":"2","key":"7673_CR285","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1124\/jpet.106.108845","volume":"319","author":"KE Merten","year":"2006","unstructured":"Merten KE, Jiang Y, Feng W, Kang YJ. Calcineurin activation is not necessary for doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: involvement of the phosphoinositide 3-kinase-Akt pathway. J Pharmacol Exp Ther. 2006;319(2):934\u201340. https:\/\/doi.org\/10.1124\/jpet.106.108845","journal-title":"J Pharmacol Exp Ther"},{"key":"7673_CR286","doi-asserted-by":"publisher","unstructured":"Miller CE, Jordan JH, Thomas A, et al. Myocardial elasticity imaging correlates with histopathology in a model of anthracycline-induced cardiotoxicity. bioRxiv [Preprint].2023.10.11.561881. https:\/\/doi.org\/10.1101\/2023.10.11.561881","DOI":"10.1101\/2023.10.11.561881"},{"key":"7673_CR287","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiomech.2023.111616","volume":"154","author":"T Artz","year":"2023","unstructured":"Artz T, Caru M, Curnier D, et al. Modelling cardiac mechanics in doxorubicin-induced cardiotoxicity following childhood acute lymphoblastic leukemia using a combination of cardiac magnetic resonance imaging, cardiopulmonary exercise testing and the CircAdapt model. J Biomech. 2023;154:111616. https:\/\/doi.org\/10.1016\/j.jbiomech.2023.111616","journal-title":"J Biomech"},{"key":"7673_CR288","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b4606","volume":"339","author":"DA Mulrooney","year":"2009","unstructured":"Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606. https:\/\/doi.org\/10.1136\/bmj.b4606","journal-title":"BMJ"},{"issue":"6","key":"7673_CR289","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","volume":"175","author":"FA van Nimwegen","year":"2015","unstructured":"van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007\u201317. https:\/\/doi.org\/10.1001\/jamainternmed.2015.1180","journal-title":"JAMA Intern Med"},{"issue":"4","key":"7673_CR290","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/sj.bjc.6605191","volume":"101","author":"T Wethal","year":"2009","unstructured":"Wethal T, Lund MB, Edvardsen T, et al. Valvular dysfunction and left ventricular changes in Hodgkin\u2019s lymphoma survivors. A longitudinal study Br J Cancer. 2009;101(4):575\u201381. https:\/\/doi.org\/10.1038\/sj.bjc.6605191","journal-title":"A longitudinal study Br J Cancer"},{"issue":"4","key":"7673_CR291","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1136\/heart.85.4.430","volume":"85","author":"J Allen","year":"2001","unstructured":"Allen J, Thomson JD, Lewis IJ, Gibbs JL. Mitral regurgitation after anthracycline treatment for childhood malignancy. Heart. 2001;85(4):430\u20132. https:\/\/doi.org\/10.1136\/heart.85.4.430","journal-title":"Heart"},{"issue":"49","key":"7673_CR292","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000009004","volume":"96","author":"X Liu","year":"2017","unstructured":"Liu X, Zhu Y, Lin X, Fang L, Yan X. Mitral regurgitation after anthracycline-based chemotherapy in an adult patient with breast cancer: a case report. Medicine. 2017;96(49): e9004. https:\/\/doi.org\/10.1097\/md.0000000000009004","journal-title":"Medicine"},{"key":"7673_CR293","doi-asserted-by":"publisher","unstructured":"Zahler D, Arnold JH, Bar-On T, et al. Valvular heart disease following anthracycline therapy-is it time to look beyond ejection fraction? Life. 2022;12(8). https:\/\/doi.org\/10.3390\/life12081275","DOI":"10.3390\/life12081275"},{"issue":"1","key":"7673_CR294","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10787-021-00894-9","volume":"30","author":"R Yang","year":"2022","unstructured":"Yang R, Tan C, Najafi M. Cardiac inflammation and fibrosis following chemo\/radiation therapy: mechanisms and therapeutic agents. Inflammopharmacology. 2022;30(1):73\u201389. https:\/\/doi.org\/10.1007\/s10787-021-00894-9","journal-title":"Inflammopharmacology"},{"issue":"5","key":"7673_CR295","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s12265-022-10231-2","volume":"15","author":"S L\u2019Abbate","year":"2022","unstructured":"L\u2019Abbate S, Chianca M, Fabiani I, et al. In vivo murine models of cardiotoxicity due to anticancer drugs: challenges and opportunities for clinical translation. J Cardiovasc Transl Res. 2022;15(5):1143\u201362. https:\/\/doi.org\/10.1007\/s12265-022-10231-2","journal-title":"J Cardiovasc Transl Res"},{"issue":"9","key":"7673_CR296","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","volume":"64","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938\u201345. https:\/\/doi.org\/10.1016\/j.jacc.2014.06.1167","journal-title":"J Am Coll Cardiol"},{"issue":"9861","key":"7673_CR297","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S0140-6736(12)60916-7","volume":"381","author":"G Heusch","year":"2013","unstructured":"Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet. 2013;381(9861):166\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(12)60916-7","journal-title":"Lancet"},{"key":"7673_CR298","doi-asserted-by":"publisher","unstructured":"Al-Malky HS, Al Harthi SE, Osman A-MM. Major obstacles to doxorubicin therapy: cardiotoxicity and drug resistance. J Oncol Pharm Pract. 2020;26(2):434\u2013444. https:\/\/doi.org\/10.1177\/1078155219877931","DOI":"10.1177\/1078155219877931"},{"issue":"7","key":"7673_CR299","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11912-020-00923-w","volume":"22","author":"JN Upshaw","year":"2020","unstructured":"Upshaw JN. Cardioprotective strategies to prevent cancer treatment-related cardiovascular toxicity: a review. Curr Oncol Rep. 2020;22(7):72. https:\/\/doi.org\/10.1007\/s11912-020-00923-w","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"7673_CR300","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/cvr\/cvaa155","volume":"117","author":"C Perrino","year":"2021","unstructured":"Perrino C, Ferdinandy P, B\u00f8tker HE, et al. Improving translational research in sex-specific effects of comorbidities and risk factors in ischaemic heart disease and cardioprotection: position paper and recommendations of the ESC Working Group on Cellular Biology of the Heart. Cardiovasc Res. 2021;117(2):367\u201385. https:\/\/doi.org\/10.1093\/cvr\/cvaa155","journal-title":"Cardiovasc Res"},{"key":"7673_CR301","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.116504","volume":"234","author":"X Li","year":"2023","unstructured":"Li X. Doxorubicin-mediated cardiac dysfunction: revisiting molecular interactions, pharmacological compounds and (nano) theranostic platforms. Environ Res. 2023;234:116504. https:\/\/doi.org\/10.1016\/j.envres.2023.116504","journal-title":"Environ Res"},{"issue":"4","key":"7673_CR302","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1159\/000531432","volume":"148","author":"JZ Li","year":"2023","unstructured":"Li JZ, Li YR. Cardiovascular protection by metformin: latest advances in basic and clinical research. Cardiology. 2023;148(4):374\u201384. https:\/\/doi.org\/10.1159\/000531432","journal-title":"Cardiology"},{"issue":"2","key":"7673_CR303","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2174\/1381612825666190312110836","volume":"25","author":"AF dos Santos","year":"2019","unstructured":"dos Santos AF, Tom\u00e9 FD, Miguel MP, et al. Doxorubicin-induced cardiotoxicity and cardioprotective agents: classic and new players in the game. Curr Pharm Des. 2019;25(2):109\u201318. https:\/\/doi.org\/10.2174\/1381612825666190312110836","journal-title":"Curr Pharm Des"},{"issue":"3","key":"7673_CR304","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/antiox10030349","volume":"10","author":"S Mirzaei","year":"2021","unstructured":"Mirzaei S, Zarrabi A, Hashemi F, et al. Nrf2 signaling pathway in chemoprotection and doxorubicin resistance: potential application in drug discovery. Antioxidants. 2021;10(3):349. https:\/\/doi.org\/10.3390\/antiox10030349","journal-title":"Antioxidants"},{"issue":"1","key":"7673_CR305","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/0008-5472.CAN-13-2620","volume":"74","author":"DH Shin","year":"2014","unstructured":"Shin DH, Choi Y-J, Park J-W. SIRT1 and AMPK mediate hypoxia-induced resistance of non\u2013small cell lung cancers to cisplatin and doxorubicin. Cancer Res. 2014;74(1):298\u2013308. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2620","journal-title":"Cancer Res"},{"issue":"8","key":"7673_CR306","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893\u2013911. https:\/\/doi.org\/10.1200\/JCO.2016.70.5400","journal-title":"J Clin Oncol"},{"issue":"12","key":"7673_CR307","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1002\/ejhf.1985","volume":"22","author":"JL Zamorano","year":"2020","unstructured":"Zamorano JL, Gottfridsson C, Asteggiano R, et al. The cancer patient and cardiology. Eur J Heart Fail. 2020;22(12):2290\u2013309. https:\/\/doi.org\/10.1002\/ejhf.1985","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"7673_CR308","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/jmri.26895","volume":"50","author":"D Jeong","year":"2019","unstructured":"Jeong D, Gladish G, Chitiboi T, et al. MRI in cardio-oncology: a review of cardiac complications in oncologic care. J Magn Reson Imaging. 2019;50(5):1349\u201366. https:\/\/doi.org\/10.1002\/jmri.26895","journal-title":"J Magn Reson Imaging"},{"issue":"9","key":"7673_CR309","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/nrcardio.2017.47","volume":"14","author":"JJ Maleszewski","year":"2017","unstructured":"Maleszewski JJ, Anavekar NS, Moynihan TJ, Klarich KW. Pathology, imaging, and treatment of cardiac tumours. Nat Rev Cardiol. 2017;14(9):536\u201349. https:\/\/doi.org\/10.1038\/nrcardio.2017.47","journal-title":"Nat Rev Cardiol"},{"key":"7673_CR310","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107895","volume":"98","author":"Q Mu","year":"2021","unstructured":"Mu Q, Najafi M. Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells. Int Immunopharmacol. 2021;98:107895. https:\/\/doi.org\/10.1016\/j.intimp.2021.107895","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"7673_CR311","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40959-023-00159-0","volume":"9","author":"A Mir","year":"2023","unstructured":"Mir A, Badi Y, Bugazia S, et al. Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: an updated systematic review & network meta-analysis. Cardiooncology. 2023;9(1):10. https:\/\/doi.org\/10.1186\/s40959-023-00159-0","journal-title":"Cardiooncology"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07673-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07673-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07673-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T10:58:35Z","timestamp":1770202715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07673-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":311,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7673"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07673-6","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"16 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}